Diet in Parkinson's Disease: Critical Role for the Microbiome

Background: Parkinson's disease (PD) is the most common movement disorder affecting up to 1% of the population above the age of 60 and 4–5% of those above the age of 85. Little progress has been made on efforts to prevent disease development or halt disease progression. Diet has emerged as a potential factor that may prevent the development or slow the progression of PD. In this review, we discuss evidence for a role for the intestinal microbiome in PD and how diet-associated changes in the microbiome may be a viable approach to prevent or modify disease progression.

Methods: We reviewed studies demonstrating that dietary components/foods were related to risk for PD. We reviewed evidence for the dysregulated intestinal microbiome in PD patients including abnormal shifts in the intestinal microbiota composition (i.e., dysbiosis) characterized by a loss of short chain fatty acid (SCFA) bacteria and increased lipopolysaccharide (LPS) bacteria. We also examined several candidate mechanisms by which the microbiota can influence PD including the NLRP3 inflammasome, insulin resistance, mitochondrial function, vagal nerve signaling.

Results: The PD-associated microbiome is associated with decreased production of SCFA and increased LPS and it is believed that these changes may contribute to the development or exacerbation of PD. Diet robustly impacts the intestinal microbiome and the Western diet is associated with increased risk for PD whereas the Mediterranean diet (including high intake of dietary fiber) decreases PD risk. Mechanistically this may be the consequence of changes in the relative abundance of SCFA-producing or LPS-containing bacteria in the intestinal microbiome with effects on intestinal barrier function, endotoxemia (i.e., systemic LPS), NLRP3 inflammasome activation, insulin resistance, and mitochondrial dysfunction, and the production of factors such as glucagon like peptide 1 (GLP-1) and brain derived neurotrophic factor (BDNF) as well as intestinal gluconeogenesis.

Conclusions: This review summarizes a model of microbiota-gut-brain-axis regulation of neuroinflammation in PD including several new mechanisms. We conclude with the need for clinical trials in PD patients to test this model for beneficial effects of Mediterranean based high fiber diets.

Introduction

Parkinson's disease (PD) is recognized as the second most common neurodegenerative disease of aging after Alzheimer's disease (AD) and the most common movement disorder, affecting up to 1% of the population above the age of 60 and 4–5% of those above the age of 85 (1, 2). While there are treatments that minimize symptoms of PD, little progress has been made on efforts to halt disease progression (3). Less than 10% of PD is associated with specific genetic changes, which means that the search is on for environmental risk factors for PD (3, 4). Diet is one such environmental factor that has emerged as a potential factor that can promote the development or exacerbate the progression of PD (5–7). In this review, we will discuss evidence for the diet involvement in PD development, discuss the mechanisms by which the diet-mediated effects on the microbiome may influence PD, and also discuss how dietary interventions may be used to prevent or treat PD.

Diet in Parkinson's Disease

There is a growing body of epidemiological evidence to support that diet impacts (positively or negatively) the development of neurodegenerative diseases such as PD. The Western diet is among the greatest risk factors for developing neurodegenerative diseases such as PD (8, 9). The Western diet is characterized by high caloric intake of energy dense foods, high in saturated and omega-6 (ω6) fatty acids, refined sugars, excessive salt intake, and low consumption of omega-3 (ω3) fatty acids and fiber (10–12). Studies of PD patients support total caloric intake of macronutrient and micronutrient correlate with symptom severity, with higher caloric intake associated with worse PD-related symptoms (13). Consumption of high quantities of animal saturated fat has been widely reported to be associated with increased risk of developing PD (14, 15). Foods associated with more rapid PD progression include canned fruits and vegetables, soda, fried foods, beef, ice cream, and cheese (all characteristic of the Western diet) (Figure 1) (9).

FIGURE 1

Figure 1. Mechanisms of communication between the intestinal microbiota and the brain. Diet robustly impacts the intestinal microbiota. Consumption of a Western diet (or components of the Western diet) promotes the growth of LPS-containing bacteria and reduces the abundance of SCFA-producing bacteria whereas consumption of a Mediterranean diet (or components of the Mediterranean diet) promotes the growth of SCFA-producing bacteria and reduces LPS-containing bacteria. This shift is highly significant because LPS-containing bacteria are pro-inflammatory, they disrupt intestinal barrier integrity and LPS binding to TLR4 stimulates a cascade of events including NLRP3 inflammasome activation, mitochondrial dysfunction, and insulin resistance culminating in neuroinflammation and neurodegeneration. In contrast, increased production of SCFA due to consumption of the Mediterranean diet (or components of the Mediterranean diet) fortifies the intestinal barrier, stimulates the intestinal L-cell production of GLP-1 and GIP which inhibits NLRP3 inflammasome activation and normalizes insulin resistance. SCFA also stimulate intestinal epithelial cell IGN and together with GLP-1/GIP stimulate the vagus nerve and brain BDNF which has numerous beneficial effects on the brain and which improves neuron insulin resistance all of which function to promote neuronal health. Characteristic features of the PD microbiome are similar to those observed following consumption of the Western diet (low SCFA-producing bacteria, high LPS-containing bacteria); therefore, dietary interventions such as the Mediterranean diet (or components of the Mediterranean diet) may be a viable approach to blunt neuroinflammation and improve neuronal function in PD. BDNF, brain derived neurotrophic factor; GIP, gastrointestinal peptide; GLP-1, glucagon like peptide 1; IGN, intestinal gluconeogenesis; IL-1β, interleukin 1 beta; LPS, lipopolysaccharide; NLRP3, nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3; ROS, reactive oxygen species; SCFA, short chain fatty acids; TLR4, toll-like receptor 4.

On the flip side, a “healthy” diet is associated with beneficial effects relative to PD (6). Adherence to the Mediterranean diet is associated with lower probability of developing PD (16). Specific components of the Mediterranean diet are particularly associated with these beneficial effects such as fresh vegetables, fresh fruit, nuts, seeds, non-fried fish, olive oil, wine, coconut oil, fresh herbs, and spices. Consumption of flavonoid-rich foods (tea, berry fruits, apples, red wine, and orange/orange juice) are also associated with a lower risk of developing PD (17). Polyunsaturated fatty acids (PUFA) are also inversely correlated with PD development (higher consumption of ω3 fatty acids is associated with reduced PD risk) demonstrating the influence of dietary fat intake on the brain (18, 19).

Diet can impact the body through multiple different mechanisms including direct effects of dietary components (e.g., vitamins, fats) on the body, but diet may modulate the development and/or progression of PD indirectly through effects on the intestinal microbiome (6, 20, 21). Indeed, diet is perhaps the single greatest factor determining the structure and metabolic function of the intestinal microbiota (22–25).

Coffee and caffeine in the diet have also been consistently associated with decreased risk of PD. Several key early studies showed a significant dose dependent decrease in risk for PD with increasing coffee consumption and for smoking as well (26–28). Recent studies have confirmed a decreased risk for PD in men and women with increasing caffeine consumption (29, 30). Both caffeine (coffee) and nicotine (smoking) have been shown to ameliorate disease in MPTP rodent models of PD (31, 32). In addition, coffee has recently been shown to contain chlorogenic acid that inhibits the NLRP3 inflammasome (33) and polyphenols that have been shown to be neuroprotective (34, 35) as well as promote healthy microbiome metabolism (36). Significantly, two recent reviews that discussed the beneficial effects of caffeine in reduced PD risk both propose a role for the microbiome (37, 38).

With regard to alcohol consumption and PD, there does not seem to be a clear conclusion. Two early large prospective studies showed no effect of moderate alcohol consumption and PD incidence (39, 40). However, another systematic review found a protective inverse relationship between alcohol use and PD (41). Another study found that heavy alcohol use was associated with decreased risk for PD (42). A recent review of all alcohol-PD studies concluded that prospective studies tended to find no association between alcohol use and PD with 2 studies finding an increased risk with moderate alcohol use and PD (43). However, the case-control studies were more likely to find a protective effect (43). Alcohol has also been shown to promote intestinal leakiness and microbiome effects (44–46). Thus, it appears there is no definitive view for the effects of alcohol consumption and risk for PD.

Consumption of dairy products is another area of diet that has evidence related to PD risk. Several studies have supported the view that high consumption of milk and possibly dairy products in general are associated with increased risk for PD (47–49). A diet study in Greece also found association of dairy and milk consumption with PD (50). Other more recent studies also supported association of dairy product consumption and increased PD risk (51, 52). A study in Hawaii found greater than two glasses of milk per day was associated with decreased neural density in the SN at autopsy (53). One proposed cause for these associations has been pesticides in the milk, but there is no data to support this. An intriguing recent study implicates microbiome bacteriophages, especially associated with Lactococcus bacteria in dairy products, as possible negative modulators of the bacterial gut microbiome in PD (54). However, a recent position paper on dairy products and PD risk concluded that overall the evidence did not warrant alarming the public to avoid dairy products (55).

There is considerable evidence that dietary or environmental exposure to neurotoxins such as rotenone and paraquat, maneb, and related neurotoxins such as MPTP can promote Parkinson's-like neurodegeneration (56, 57). All of these neurotoxins target the mitochondria and there is longstanding evidence that mitochondria dysfunction is critical in PD development (58, 59). Dysfunctional mitochondria activate the NLRP3 inflammasome (60). Both the herbicide paraquat and antifungal maneb have been linked to PD (56). Rotenone, a broad based pesticide, is currently used in animal models of PD (61, 62). MPTP, which also targets the mitochondria like the other neurotoxins listed, is also widely used as a model for PD (63, 64). There is a large body of epidemiological and experimental evidence for increased risk of PD due to environmental and dietary exposure to these neurotoxins (63–66). An early study found that exposure to pesticides resulted in a 70% increased risk for PD (67). These neurotoxins have been shown to cause Parkinsonian symptoms and SN neurodegeneration when injected systemically or directly into the striatum (62, 64). However, the effects of these environmental toxins on the microbiome has not been studied in depth. Significantly, in a PD mouse model of oral gavage administered rotenone, marked changes in the microbiome correlated with disease markers and TLR4 expression in the intestine and SN neuron loss (68, 69). Studies by this group also showed that a uridine and fish oil diet could ameliorate PD symptoms in these mice (61). In another rodent study using rotenone IP injection, changes were also found in the intestinal microbiome similar to those in PD patients (70). These studies support the model that both oral and systemic injection of these neurotoxins/pesticides can affect the microbiome. Another recent study showed that the pesticide diazinon could modulate the microbiome community in mice (71). Thus, the effects of these neurotoxins on the intestinal microbiome appears to be an important area for future study.

Recently the possibility of α-Syn in diet has become a focus of potential causes of PD (72). α-Syn is a 140 AA protein found in the brain as well as in lesser amounts in heart, muscle and other tissues and dairy products (72, 73). The function of α-Syn is unknown but hallmark inclusions known as Lewy pathology are found in neurons of the SN in PD and it is believed to play a role in PD (74). α-Syn aggregates can take many forms but it appears as though the fibrillar (PFF) form may be the most pathogenic in the brain because injection of this form can cause PD symptoms and pathology (75–77). Several studies support a possible spread of α-Syn with prion like properties and mutations in the α-Syn gene are associated with familial PD (78, 79). Recent experiments show injection of α-Syn PFF in the stomach or intestine traffic to the brain via the vagus nerve in rodents (80, 81). If α-synuclein spreads via a prion-like mechanism, then one question becomes, what are the origins of this prion-like species? One source could be meat products (72). First, it should be noted that no study has quantified the amounts of intact α-Syn in the stool. It may be that it is degraded by digestive functions and not available for uptake or absorption by the intestines. If it does remain intact, one possibility is α-Syn uptake by gut M cells. M cell depletion prevents oral prion infectivity (82). Also T cells in the gut and dendritic cells expressing LAG3 could bind α-Syn and promote its spread (83). Leaky gut could also be a mechanism for α-Syn translocation to the systemic circulation (84). Overall, research to date has yet to directly test the contribution of dietary α-synuclein to the mechanism of initiation and progression of PD (72). However, α-Syn is found in beef, pork, chicken, and fish and many people regularly consume these meat and dairy products, but only a small fraction of the general population will develop PD. Therefore, it is unlikely that eating meat products that contain α-Syn is an independent cause of PD (72). Nonetheless, future studies tracking α-Syn in the diet systemically as well as in the intestinal tract could provide new insights to a role for this key PD protein as a potential dietary risk factor.

Diet and the PD Microbiome

The human gastrointestinal tract (GIT) harbors trillions of microorganisms collectively referred to as the microbiome (24, 85, 86). We have a symbiotic relationship with the microbiota (the bacterial component of the microbiome). We provide them with an environment (the GIT) and food and they provide us with a myriad of benefits. The microbiota helps ward off harmful microorganisms (competitive exclusion), regulate immunity, and produce substances such as vitamins, secondary bile acids, and short chain fatty acids (SCFA) (24). For example, dietary fiber is used as a food source by the intestinal microbiota. Dietary fiber is a general term for consumed plant-based complex carbohydrates that are largely not digested by mammalian enzymes in the small intestine and consequently cannot be absorbed. However, they are available to be used as a food source by the intestinal (colonic) microbiota (87). Colonic bacterial fermentation of these dietary fibers generates metabolic byproducts and especially important are SCFA (10, 87–89). In contrast to these beneficial commensal bacteria, there are also pathogenic bacteria (pathobionts) that can cause GIT dysfunction (intestinal barrier dysfunction) and inflammation in the intestinal mucosa, systemic circulation, and even in the brain (10, 90). Thus, the balance of microbiota influences not only the GIT, but also organs throughout the body including the brain (91).

Although no two human microbiota communities are identical (influenced by lifestyle factors like diet, exercise, and genetics), recent studies in the last 10 years have shown people with certain diseases tend to share similar characteristic microbiota features (24, 92). An abnormal microbiome (so called “dysbiosis”) is associated with many human diseases such as obesity/metabolic syndrome, inflammatory bowel disease (IBD) and other chronic inflammatory diseases as well as in PD (90, 93, 94). The intestinal microbiota has become a major focus of PD studies (95, 96). Initial studies by Scheperjans et al. (97) and Keshavarzian et al. (98) reported abnormal intestinal microbiota composition (dysbiosis) in PD patients. Subsequently, 15 additional studies from the USA, Europe and Asia have also demonstrated dysbiosis in PD patients (Supplementary Table 1) (95, 96). As detailed in Supplementary Table 1, the PD patient's microbiota composition alterations are not identical in all of these studies. This is not surprising and should be expected because of the significant intra- and inter-individual variability discovered in the microbiota composition of healthy control subjects (99, 100) and other diseases, where intestinal dysbiosis has been reported (90, 92). Environmental factors, especially diet, can markedly affect microbiota community structure and composition, and thus it is expected that the intestinal microbiota in patients from the USA should be different from those living in Europe or Asia (21, 101). In fact, the intestinal microbiota was found to be significantly different in individuals living in different communities in the city of Chicago, Illinois, USA (102). The important key finding is that patients with PD have abnormal intestinal microbiota communities (“dysbiosis”) regardless of where they live and also the PD microbiota community appears abnormal still after 2 years of follow up (103, 104). The majority of PD human studies employed bacterial 16S ribosomal RNA (rDNA amplicons) sequencing to different variable regions to identify bacteria in feces (majority of studies), colonic sigmoid mucosa (98), nasal wash (105) or nasal swab and oral (106, 107) samples. Three studies used targeted quantitative PCR, while one study utilized metagenomics shotgun sequencing. Regardless of sequence technique or bioinformatics methodologies, the overall common discovery indicated dysbiotic bacterial profiles, which suggested putative pro-inflammatory bacteria were more abundant and putative beneficial bacteria were less abundant in PD patients.

Parkinson's disease subjects demonstrated significantly altered intestinal microbial compositions in comparison to healthy controls with some overall trends worthy of comment. Briefly these include PD subjects to exhibit: increased relative abundance of genera Akkermansia (7 studies) (98, 105, 108–112), Bifidobacterium (5 studies) (103, 108, 110, 113, 114), and Lactobacillus (7 studies) (97, 103, 110, 111, 113, 115, 116); decreased abundance of genus Prevotella (7 studies) (97, 103, 104, 108, 109, 113, 117) and the family Lachnospiraceae (6 studies) (98, 103, 110, 111, 114, 117) along with its lower taxonomic hierarchal putative SCFA-producing genera Faecalibacterium (5 studies) (98, 108, 110, 113, 117), Roseburia (4 studies) (98, 103, 110, 111), Blautia (5 studies) (98, 103, 110, 113, 117), Coprococcus (2 studies) (98, 113), and Dorea (2 studies) (98, 113) (Supplementary Table 1).

Significantly, a few of the studies evaluated predicted functional gene content profiling (PICRUSt) (118) to infer changes in microbiota function. Keshavarzian et al. discovered PD subject's fecal samples had significantly higher abundant genes involved in lipopolysaccharide (LPS) biosynthesis, with a large number of genes involved in metabolism were significantly less abundant (98). Hill-Burns et al. indicated 17 upregulated pathways and 9 downregulated pathways, including xenobiotics degradation and metabolism of plant-derived compounds in PD subjects (110). Barichella et al. revealed 11 upregulated pathways and 15 downregulated pathways in de novo PD subjects, compared to healthy controls (111). Qian et al. predictive functional analysis indicated four metabolic pathways upregulated and 3 pathways downregulated (119). Finally, Bedarf et al. used the detailed metagenomics shotgun analysis to infer functional analyses of the metagenomes that showed differences in microbiota metabolism in PD subjects involving the β-glucuronate and tryptophan metabolism (109).

The intestinal microbiota does not appear to be the only microbiota that is disrupted in PD patients. To date, there are two studies that interrogated the nasal and oral microbiota community structure and composition in PD patients. Pereira et al. interrogated both nasal and oral microbiota profiles between PD patients and healthy controls (107). The oral microbiota composition was significantly altered in PD patients, compared to healthy controls, predominantly by higher relative abundance of opportunistic pathogens. The nasal microbiota lacked strong significant individual taxa differences, but trended toward an overall difference in the microbial composition between groups. In contrast, Mihaila et al. interrogated the oral microbiota using saliva samples through shotgun metatranscriptomic profiling and found significant changes in the microbiota community structure, composition and function in PD patients (106). The study found several similarities between dysbiotic oral microbiota and dysbiotic fecal microbiota in PD patients, when they compared their findings with previously published human PD studies. Dysbiotic oral microbiota once again was characterized by higher relative abundance of putative pro-inflammatory bacteria. This finding is potentially important in PD pathogenesis because one proposed site of initial injury in PD is the olfactory bulb, which is in close proximity to the oronasal space, as proposed by Braak et al. (120, 121).

However, the causal link between dysbiotic microbiota and the development of PD is yet to be established. The debate is whether these changes in microbiota community structure and composition in PD starts the trigger for PD, or are a consequence of PD. Indeed, several studies have shown a correlation between changes in microbiota and duration of the disease and dysbiosis is more pronounced in those with longer duration of PD (98, 104, 115, 117). This is not surprising because PD patients commonly change their life habit to better cope with their symptoms and this life style change can impact microbiota composition. For example, GI symptoms are common in PD patients (122, 123) and thus they typically change diet that could affect their microbiota. Although several studies did not find a correlation between diet and dysbiosis in PD patients numerous studies support a role for Western diet and possibly dairy products in PD risk (47, 51, 61, 124, 125). Constipation is very common in PD patients and typically occurs years before onset of CNS symptoms (123, 126, 127) and constipation can impact the microbiota community (128). However, dysbiosis was also found to occur in those PD patients who did not suffer from constipation (98). Patients with PD have poor sleep and reversal of sleep/wake cycles that can cause disruption of circadian rhythms (129, 130) and both disrupted sleep and circadian disruption can cause dysbiotic microbiota in both humans and rodents (131, 132). Additionally, PD medication correlates with dysbiosis (105, 110, 119). However, dysbiosis was still present in early onset and naïve PD patients on no PD medication (98). More importantly, dysbiosis has been reported in patients with idiopathic rapid eye movement sleep disorder (iRBD) (prodromal PD) (105). Thus, even though life style changes from PD symptoms and PD medication may contribute to changes in microbiota composition, it does not appear to explain the observed dysbiosis in PD patients. Taken together, these findings support the hypothesis that abnormal microbiota composition plays a critical role in the pathogenesis of PD and is a major contributor of symptomatic PD development.

One key question is how does the intestinal microbiota dysbiosis observed in multiple PD studies arise? The current model for a role for the microbiome in PD is that dysbiosis may be driving PD progression either via systemic inflammatory factors and/or increased α-Syn misfolding in the gut that results in aggregates of α-Syn being transported to the brain via the vagus nerve as hypothesized by Braak (95, 120). However, there is no established mechanism to explain the intestinal microbiome dysbiosis or even to what extent it is a consequence or cause of PD (95, 96, 133). Studies in which PD patient fecal transplant into genetic PD mice worsened the PD phenotype support a role for microbiome dysbiosis directly promoting PD progression (134). One possibility is a genetic contribution considering that LRRK2 polymorphisms are associated with PD risk and IBD risk and LRRK2 mediates microbial immune signaling. But the majority of sporadic PD appears to be associated with environmental risk factors that also affect the microbiome such as stress, diet, lack of exercise, and disruption of circadian rhythms seen in REM sleep behavior disorder (RBD) (4, 105, 135–137). Change in life style with PD that helps patients to cope with symptoms can affect microbiota-like lack of exercise and change in diet- these changes can explain worsening of dysbiosis in those with a long duration of PD but also in early onset PD (138). Gut dysfunction also can affect microbiota and constipation (128) could be a contributing factor and several studies link prodromal constipation with PD (123, 126). However, constipation cannot explain dysbiosis completely because PD patients without constipation still had dysbiosis and leaky gut (84, 98). Also, PD patients with RBD who had no constipation still exhibited dysbiosis (105). Thus, while the search goes on for mechanisms for PD dysbiosis, the most likely cause is Western lifestyle factors known to affect the microbiome including stress, Western diet, lack of exercise, and circadian disruption (4, 136).

Microbiota-Gut-Brain Axis in PD

Recent models for PD pathogenesis have focused on the important role of the microbiota-gut-brain axis (MGBA). One school of thought, originally proposed by Braak et al. (120) actually proposes that PD originates in the GIT or possibly the nasal mucosa (121) and spreads to the brain (139, 140). In support of this model several studies have shown α-Syn protein exhibits prion-like properties and cell to cell transmission (141). Key papers showed inter-neuronal trans-synaptic transport of α-Syn in pathological studies in PD patients that had received striatal transplants supporting the spread of misfolded α-Syn to normal adjacent cells (142–144). Recent studies have now shown EE cells of the gut can produce misfolded α-Syn and synapse with enteric nerves to transmit α-Syn (14, 145). However, the true role of α-Syn in PD is still debated (146). The role of α-Syn in the intestine is discussed further below. The MGBA is the two-way communication between the GIT and the CNS/brain and consists of many mechanisms (6, 147, 148). The mechanisms of communication used by the MGBA include responses to bacterial components and bacterial metabolites (including pro-inflammatory products like LPS that could activate microglia and trigger neuro-inflammation) (149–151) and anti-inflammatory products like SCFA, especially butyrate (152), peptides [including neurotransmitters and neuromodulators such as g-aminobutyric acid (GABA)], serotonin, dopamine (151, 153) and hormones produced by cells of the GIT (154, 155). This interaction includes bidirectional microbiota–immune interaction and microbiota-nervous system interaction. In fact, a growing number of studies support two-way interaction of the microbiota with virtually every organ system (24). This bidirectional communication is increasingly acknowledged as playing an important role in brain function including in neurodegenerative diseases (147, 151).

Evidence supports that virtually every part of the GIT is affected in PD (122, 123). A pathologic hallmark of PD are so called Lewy bodies in the brain substantia nigra (SN) neurons that are found post-mortem. Lewy bodies are largely composed of the neuronal protein alpha synuclein (α-Syn). A key feature in PD is that aggregated and phosphorylated forms of α-Syn protein have also been observed in every major part of the GIT and enteric nervous system in patients with PD (84, 123, 156–158). For example, Lewy bodies/Lewy neurites are present in 72–100% of intestinal samples from PD subjects and 62% have phosphorylated α-Syn which is markedly greater than that observed in the healthy population (0–33% have α-Syn). These data suggest that intestinal synucleinopathy may be a relatively sensitive and reliable indicator of PD (123, 159). Importantly, increased phosphorylated α-Syn is also found in GIT tissues from prodromal PD patients suggesting that GIT involvement occurs early in disease pathogenesis (159, 160). This is supported by a recent study which reported that distinctive α-Syn immunoreactivity observed in intestinal biopsies collected from healthy individuals who would later go on to develop PD (156, 157). Taken together, these data support the idea that abnormal enteric α-Syn appears before neurodegeneration in CNS advances to a point that is sufficient for motor symptoms to emerge. Such data also support an intestinal origin for PD.

Motor impairments in PD are generally preceded by non-motor symptoms such as depression, olfactory deficits, sleep behavior disorder, and a number of GIT symptoms. The GIT symptoms can precede motor symptoms by more than 10 years and include GIT motility problems, colonic inflammation, and constipation (50–80%) (123, 127, 161). In fact, constipation is associated with a 2.7- to 4.5-fold increase in the risk of developing PD (123).

In 2003, Braak et al. postulated that an unknown pathogen (virus, bacterium) or toxin originating in the GIT or nasal passage/olfactory nerve (two hit hypothesis) could be responsible for the initiation of sporadic PD (120, 121). In this model of disease progression, the pathology initiates in the GIT (or nasal/olfactory) and propagates to the brain via the Vagus nerve or olfactory nerve (120, 162). Researchers have demonstrated that α-Syn fibrils, injected into the GIT mucosa of rodents, can propagate through the Vagus nerve and can be found in the brain (81, 163). Another recent study injected pre-formed α-Syn fibrils into the mouse stomach mucosa and found progressive PD pathology including α-Syn misfolding in the Vagus nerve and SN, an effect that was absent in vagotomized mice (80). With regard to vagotomy and risk of PD, a study by Svensson et al. found that full truncal vagotomy is associated with a decreased risk for subsequent PD, supporting that the vagal nerve may be critically involved in the pathogenesis of PD as proposed by Braak et al. (120, 164). However, two subsequent studies have disputed these findings. Tysnes et al. reanalyzed these data and found no significant risk reduction for PD with vagotomy (165). In addition, a second independent human study in Sweden found no decreased risk for PD after vagotomy (166). Thus, vagal involvement in PD disease development is still disputed (133).

However, even if the Vagus nerve isn't critical in initiating or promoting α-Syn PD pathology there are many other mechanisms by which the GIT can impact the brain via the vagus as we discuss below. The changes observed in the GIT in humans and animal models of PD are intriguing and begs further investigation into what is causing the GIT dysfunction and α-Syn aggregation to occur (140). One possible factor is the intestinal microbiota (95, 96).

A growing body of evidence now supports that the intestinal microbiota modulates behavior and contributes to neurological disorders and neurodegenerative diseases (151, 167–169). In fact, data show that the intestinal microbiota is necessary for the development of PD-like behavior and pathology in rodent models. Specifically, germ-free mice and antibiotic-treated mice have ameliorated PD-like behavior and pathology compared to their specific pathogen free counterparts (134). These data suggest that signaling between the microbiota and the brain is critical for PD-like outcomes in rodent models. It also appears that there is something remarkable about the PD microbiome that triggers events leading to neuroinflammation and neurodegeneration. Transfer of a microbiome from an MPTP-treated mouse into a control (non-MPTP) mouse is sufficient to induce motor impairment and activation of microglia and astrocytes in the SN (170). In addition, colonization of α-Syn-overexpressing (ASO) mice with microbiota from human PD patients enhances motor impairments compared to mice that received microbiota transplants from healthy human donors (134). These findings support that intestinal microbiome can regulate the development of PD-like pathology and behavior in mice and therefore may also be important in contributing to disease development in humans (95, 96). Perhaps PD should no longer be viewed solely as a complex disorder of motor functions, but rather as a progressive condition involving the GIT (6, 148, 171).

GIT-derived bacteria, bacterial components, and bacterial metabolites can trigger neurodegeneration through multiple pathways which are affected by diet and discussed below. First, is the intestinal barrier mechanism. In this mechanism, bacterial components (e.g., LPS) and bacterial metabolites (e.g., SCFA) produced by the microbiota influence intestinal barrier integrity which directly contributes to inflammation in the systemic circulation and in the brain (91, 137, 172). Second, is the NLRP3 inflammasome activation mechanism. Endotoxemia (i.e., LPS in the blood) resulting from barrier dysfunction activates the NLRP3 inflammasome and results in mitochondrial dysfunction and IL-1b production and insulin resistance with important consequences for neuronal function (77). Finally, are the intestinal peptide and intestinal gluconeogenesis mechanisms (173, 174). Bacterial metabolites influence the production of the GIT peptide production, insulin resistance, mitochondrial function, and vagal stimulation of brain derived neurotrophic factor (BDNF) production in the brain. This list of potential mechanisms is by no way means exhaustive but reflects key topics that are rapidly emerging as factors contributing to diet-microbiome regulation of gut-derived inflammation in neurodegeneration and PD.

Intestinal Barrier Mechanism

The intestinal epithelial barrier separates the pro-inflammatory luminal contents (e.g., LPS) from reaching the intestinal and systemic circulation, and the intestinal microbiota is a critical regulator of intestinal barrier integrity (91, 175). Intestinal barrier dysfunction (i.e., intestinal leakiness) has been observed in newly diagnosed, untreated PD patients which is also associated with increased LPS staining and α-Syn aggregates in the colonic mucosa (84). GIT dysfunction has also been described in animal models of PD including in both genetic and toxin-induced models (122, 123) which occurs concurrently with α-Syn aggregations in the GIT (123). These observations further support the hypothesis that PD may originate in the GIT (139).

Indeed, intestinal microbiota dysbiosis (especially when characterized by a reduction in SCFA-producing bacteria that has been reported in PD patients) is associated with intestinal barrier dysfunction and endotoxemia (i.e., LPS in the blood) (91, 95). Specifically, bacterial production of SCFA appear to be critically important in regulating the barrier (87). The three principal colonic SCFA include acetate (2-carbon), propionate (3-carbon), and butyrate (4-carbon). These typically exist in the colon in a millimolar ratio of 60:20:20 (acetate:propionate:butyrate) (176). Two other important SCFA receiving are lactate and succinate. SCFA exert beneficial effects through multiple mechanisms (87). Previous reviews of SCFA mechanisms have focused on SCFA specific GPCR signaling via specific receptors: GPR41 (propionate/butyrate), GPR43 (acetate/propionate), and GPR109a (butyrate) for acetate, propionate, and butyrate (87, 177). Also GPR81 (lactate) and GPR91 (succinate) have received recent attention (87). These GPCR for SCFA are reviewed in detail elsewhere (87, 177). Broadly speaking, SCFA GPCR positively modulate immunity and anti-inflammatory signaling in immune and other cells as well as mitochondrial cellular metabolism (178, 179). Butyrate (and to a lesser extent propionate and acetate) also has histone deacetylase inhibitor (HDACi) activity that can have epigenetic effects on gene expression, and butyrate is used by colonocytes as an energy source (10, 177). It is through these mechanisms that SCFA (especially butyrate) influences intestinal barrier integrity. Indeed, a reduction in putative SCFA-producing bacteria or a reduction in luminal SCFA (due to intestinal microbiota dysbiosis) is associated with intestinal barrier dysfunction (10, 87, 180).

Diet-induced dysbiosis or even age-associated dysbiosis (a normal feature associated with aging) (91, 175), are characterized by a loss of SCFA-producing bacteria and SCFA, these may be able to trigger intestinal barrier dysfunction and subsequent inflammatory events leading to systemic inflammation as well as neuroinflammation and neurodegeneration (101, 175). Newly diagnosed, treatment naive PD subjects have evidence of intestinal barrier dysfunction compared to age matched controls (84, 181). Specifically, PD subjects have elevated levels of serum LPS binding protein (LBP, binds to LPS to elicit an immune response), abnormal intestinal tight junction proteins, fecal markers of leaky gut, serum zonulin, as well as E. coli in the intestinal mucosa compared to age matched controls (84, 181, 182). In support of intestinal barrier dysfunction being a critical mechanism, diseases characterized by intestinal microbiota dysbiosis and barrier dysfunction are a risk factor for developing PD. Specifically, Four studies in patients with inflammatory bowel disease (IBD), which is also characterized by intestinal microbiota dysbiosis and barrier dysfunction, support a significantly increased risk for developing PD compared to people without IBD (183–186). Also, a recent systematic review and meta-analysis of these four IBD-PD studies above concluded that the overall risk of PD in IBD was significantly higher than controls. Crohn's disease had a 28% increased risk of PD and ulcerative colitis had a 30% increased risk of PD compared to controls (187). In support of these data two studies using the DSS rodent model of ulcerative colitis concluded that DSS in drinking water and the resulting intestinal inflammation exacerbated symptoms of PD in both the LPS-striatum injection PD model (188) and an α-Syn overexpressing genetic PD model (189). However, in one recent US study using a large Medicare database analysis and newly diagnosed PD patients, IBD was associated with lower risk of PD as were Crohn's disease and Ulcerative colitis individually (190). The reasons for these differences are not clear and the role of IBD in PD risk remains to be defined. Studies have also demonstrated that a genetic variant that is a risk factor for IBD (leucine rich repeat kinase 2, LRRK2, important in the response to microbial ligands), is also a risk factor for PD (191). Furthermore, restraint stress (which caused intestinal barrier leak) exacerbated PD-like symptoms and loss of dopaminergic neurons in the striatum in the rotenone rodent model of PD (137).

Endotoxin in the blood (as a consequence of intestinal barrier dysfunction) can affect the brain directly (101, 149, 175). Like PD, Alzheimer's disease (AD) is a neurodegenerative disease that is also characterized by intestinal microbiota dysbiosis and barrier dysfunction (192, 193). Recent post mortem analysis of AD patient brains reveals LPS staining in the hippocampus and cortex of AD patients is 21-fold greater than that observed in control brain tissue (150, 194). Like AD, PD is also characterized by intestinal barrier dysfunction and endotoxemia (84), therefore it is possible that intestinal barrier dysfunction may play a key role in PD development and/or progression (95).

Mechanistically, Western diet dysbiosis, intestinal barrier dysfunction and endotoxemia can lead to immune activation and neuroinflammation (91, 101, 195–197). Toll like receptors (TLRs) recognize pathogen associated molecular patterns (PAMPs) located on the surface of bacteria (198). Among the most widely studied is the interaction between TLR4 and LPS (199). TLRs are located on a wide variety of cell types and are critical to mount an appropriate immune response to bacteria. In fact, administration of systemic LPS has been used as a model for PD for many years (149, 197, 200). Mechanistically, this appears to be the consequence of LPS-driven activation of TLR4, especially on brain microglia (201). Specifically, TLR4 knock out mice are protected from the effects of oral low dose rotenone as well as MPTP including less neuroinflammation and neurodegeneration, compared to rotenone-treated, wild-type mice (68, 202). These data support that TLR4 receptors are important in the development of PD-like pathology.

Taken together, it appears that barrier dysfunction, leading to endotoxemia, and TLR4 receptor activation may result in a series of events culminating in systemic inflammation and neuroinflammation and neurodegeneration (91, 101, 203–205). Even if intestinal barrier dysfunction is a consequence of PD (and not an initiating trigger/cause), intestinal barrier dysfunction and the resulting endotoxemia may still produce sustained neuroinflammation that promotes PD disease progression (101, 203).

NLRP3 Inflammasome Activation Mechanism

One of the consequences of TLR activation is microglial NLRP3 inflammasome activation (77, 206). In response to activation of TLRs, the NLRP3 inflammasome assembles and produces inflammatory cytokines (207, 208). Among the most widely studied inflammasomes is the NLRP3 inflammasome which produces pro-inflammatory cytokines especially IL-β as well as IL-1α, IL-18, and IL-33 (209). Inflammasomes are present in peripheral immune cells such as macrophages, as well as in the brain and especially in microglia (206, 210, 211). A role for microglial NLRP3 inflammasome in PD has recently been proposed (77). The NLRP3 inflammasome has also emerged as a potential driver of α-Syn neuroinflammation in PD (212). The current model of NLRP3 activation proposes a “two signal” model (213). In this model, TLR signaling is the first signal which induces NF-kB-mediated expression of pro-IL-1β and pro-IL-18. The second signal can be ATP, calcium or potassium flux or mitochondrial reactive oxygen species (ROS) which can occur as a consequence of a number of factors such as intestinal microbiota dysbiosis, endotoxemia (11, 213–217) or other factors that induce mitochondrial dysfunction such as aging (60, 218). Another possible second signal is misfolded α-Syn (aggregated α-Syn) that was induced by TLR/NF-kB mediated inflammation (77, 212). The second signal induces NLRP3 assembly and subsequent caspase-1 activation. The combination of the first and the second signals results in cleavage of pro-IL-1β to its active form IL-1β (and other cytokines like IL-18) (213) which has a wide range of biological consequences including creation of sustained pro-inflammatory/oxidative stress in the brain that would lead to more α-Syn aggregation, more neuro-inflammation enough to cause DA loss and neurodegeneration and symptoms of PD (77).

There is a substantial amount of data demonstrating the importance of the NLRP3 inflammasome in PD. Recent post mortem studies in PD patients show that the NLRP3 inflammasome is significantly upregulated in the SN of PD patients (almost entirely localized to microglia) (77). This upregulation in NLRP3 was also observed in mouse models of PD and AD (77, 219) and it appears to be important in disease pathogenesis. Specifically, inhibition of NLRP3 protects against neurodegeneration in all rodent models of PD tested including injection of pre-formed α-Syn fibrils (PFF), rotenone, and MPTP models (77, 215, 220). Similarly, knocking out NLRP3 in an AD animal model (another neurodegenerative disease) protects mice from developing AD-like behavior and brain pathology (219). Thus, activated NLRP3 inflammasome appears to be a key driver of neuroinflammation in PD (77, 220). In addition, NLRP3 levels also appear to increase with other factors such as age and consumption of a Western diet, it could be that the increase in NLRP3/IL-1b reduces the resiliency of the brain to respond to a secondary insult such as gut-derived endotoxemia from microbiota dysbiosis and/or intestinal barrier dysfunction (11, 221, 222).

In addition to LPS activation of TLR4, the microbiota can also influence the NLRP3 inflammasome by producing secondary bile acids. Primary bile acids are produced in the liver and are subsequently released into the GIT to aid in the digestion and absorption of lipids. Most primary bile acids are absorbed in the small intestine but those that reach the colon are metabolized by the intestinal microbiota to form secondary bile acids. Importantly, secondary bile acids can inhibit the NLRP3 inflammasome via the TGR5 receptor and are dysregulated in Western diet induced dysbiosis (223, 224).

As already mentioned, NLRP3 activation results in production of several cytokines but perhaps the one that may be most relevant for PD is IL-1β. IL-1β is not only a potent pro-inflammatory cytokine and thus a major player in neuro-inflammation in PD, but also has many other biological effects. Among the many consequences of IL-1β production is the development of insulin resistance (218). Specifically, IL-1β blocks signaling associated with insulin receptors. Activation of NLRP3 and subsequent IL-1β production are the single greatest factors that drive insulin resistance, and NLRP3 KO mice are protected from developing insulin resistance (225, 226). Specifically, cytokines, especially IL-1β, block insulin signaling which has important detrimental consequences on neuronal mitochondrial function and cellular health. In fact, insulin resistance is characteristic of both the PD and AD brain (227–229) and diabetes is a risk factor for development of PD (228).

Insulin resistance and type 2 diabetes mellitus (T2DM, characterized by insulin resistance) may cause neuroinflammation by driving mitochondrial dysfunction, leading to excessive production of ROS, cellular stress, NLRP3 activation and neuroinflammation (especially via microglia), ultimately culminating in neuronal dysfunction and death (228, 229). Insulin resistance is commonly observed during aging, but it may also be important in the pathogenesis of PD (229). The incidence of both T2DM and PD are both increasing in Western societies suggesting that these two diseases may be related (230). In fact, as noted, T2DM is a risk factor for PD and is characterized by intestinal microbiota dysbiosis similar to that observed in PD (loss of SCFA-producing bacteria, increase in LPS-containing bacteria) (231–236). Premature cognitive decline is also a feature commonly observed in patients with T2DM (231). Inhibition of NLRP3 (via glyburide or pioglitazone, the SCFA butyrate, or MCC950) prevents the development of insulin resistance and T2DM as well as PD (77, 211, 237–240). Taken together, these data support a model for a cascade of events culminating in intestine-derived neuroinflammation and neurodegeneration. Specifically, LPS-TLR activation of the NLRP3 inflammasome induces production of IL-1β resulting in insulin resistance, mitochondrial dysfunction, and ROS production, further NLRP3 activation and neuroinflammation and neurodegeneration.

Intestinal Peptide and Intestinal Gluconeogenesis Mechanisms

Influence of diet and the intestine on brain function (gut-brain axis) is not necessarily limited through intestinal microbiota. The intestine produces a number of substances that directly or indirectly influence the brain. These substances are produced in response to dietary components (e.g., fats) but also are produced in response to bacterial metabolites. Bacterial products, SCFA and secondary bile acids, can both promote the production of the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose dependent insulinotropic polypeptide (GIP) by L-cells of the GIT (87, 241–243). GLP-1 and GIP impact a number of cell types that can directly or indirectly affect neuroinflammation and neurodegeneration in PD.

GLP-1 has multiple mechanisms of action. One important consequence of GLP-1 production is reduced inflammation. For example, stimulation of the GLP-1 receptor (via GLP-1 or agonists) inhibits the NLRP3 inflammasome (244–246). In so doing, GLP-1 prevents the cascade of events including IL-1β production culminating in insulin resistance, mitochondrial dysfunction and cellular stress. GLP-1 also corrects insulin resistance by stimulating pancreatic cells to produce insulin and normalizing insulin signaling and mitochondrial function in brain neurons (247). Normalizing insulin resistance improves mitochondrial function and reduces ROS production, which has the net effect of blocking neuroinflammation and improving neuronal health. GLP-1 can have effects within the brain itself because it can cross the blood brain barrier and receptors for GLP-1 are located on neurons, astrocytes, and microglia (247–249). GLP-1R-deficient mice show impaired performance in memory-related behavioral tasks (248). In addition, GLP-1 is protective against neuronal apoptosis in the Alzheimer's disease model (247). Finally, stimulation of GLP-1 receptors induce production of BDNF in the brain and also stimulate vagal signaling from the gut to further promote brain BDNF (247, 248). BDNF is a critical factor for survival and health of dopaminergic neurons in the SN (250). Indeed BDNF is dramatically decreased in PD brain tissue, thus, the ability to increase BDNF is an important consequence of GLP-1 production (250, 251).

Alterations in GLP-1 signaling are associated with many features associated with PD or risk factors for developing PD. For example, intestinal microbiota dysbiosis disrupts normal GLP-1 signaling (252), reduced GLP-1 production is associated with metabolic syndrome (insulin resistance) (253), and reduced GLP-1 is associated with reduced BDNF in the brain (254). On the flip side, GLP-1 agonists are protective in several rodent models of PD (174, 247). Agonists of GLP-1 and dual treatment of GLP-1/GIP demonstrate neuroprotection in MPTP models of PD (255, 256). It is possible that these effects are mediated through a mechanism involving both inhibition of NLRP3 and an increase in the production of glial derived neurotrophic factor (GDNF) and BDNF and may involve GLP-1 induced improvement in insulin sensitivity as well as GLP-1 vagal stimulation (174). Importantly, recent clinical trials show that GLP-1 agonists elicit significant improvements in PD patient disease scores compared to placebo (248, 257, 258).

Intestinal gluconeogenesis (IGN) is also a mechanism by which the diet and microbiota can influence neuroinflammation and neurodegeneration. Recent studies have shown that the SCFA (butyrate, propionate) can regulate host metabolism by stimulating IGN in intestinal epithelial cells that in turn promotes vagal signaling (173). It should not be surprising then that a healthy high fiber diet and increased gut SCFA can correct insulin resistance via both IGN-vagal-BDNF signaling and by GLP-1/GIP stimulation and preventing intestinal leakiness and NLRP3 activation (10, 87, 259). IGN vagal BDNF stimulation is a key mechanism by which IGN may promote normal brain glucose metabolism which is dysregulated in PD (173). Thus, IGN from gut SCFA can also influence BDNF production in the brain via the vagus (260). BDNF promotes neuronal cell health and normal insulin signaling in the brain (261). It makes sense then that impaired insulin sensitivity in the PD brain is associated with low BDNF levels (250, 262–264).

There are multiple mechanisms by which GLP-1, GIP, and IGN can influence the brain but it is interesting that they all share the feature of being able to upregulate production of BDNF (262). BDNF is also a key neurotrophic factor in CNS degeneration and regeneration (262). Reduced levels of serum BDNF are observed in PD patients compared to healthy controls, including in the serum and in the brain (SN, caudate-putamen) (251, 265, 266). It is intriguing to think that Western diet intestinal microbiota dysbiosis leading to low SCFA production might blunt the expression of BDNF through a mechanism involving gut leakiness and loss of GLP-1, GIP, and/or IGN. Western diet dysbiosis also results in loss of (fewer) gut vagal afferents in rats (267). Finally, it is noteworthy that GLP-1, GIP, and IGN and other intestinal hormones are largely influenced by diet and dietary intervention such as switching from primarily animal-based Western diet to primarily plant-based diet can promote normal homeostasis of these hormones. These data are yet another scientific rationale for considering dietary intervention to prevent/treat or at least modify disease course in PD.

Diet as a Prevention or Treatment for PD

Based on these data it is clear that there are several mechanisms by which intestinal bacteria, bacterial products, or bacterial metabolites and intestinal hormones can influence neuroinflammation and neurodegenerative processes. Therefore, it seems logical that dietary interventions targeted at modifying the intestinal microbiota structure and/or function and intestinal peptides may modify PD disease pathogenesis. Indeed, Hippocrates' said: “Let food be thy medicine and medicine be thy food” (10). Diet has recently gained importance as a risk factor for developing PD and also as a potential therapeutic approach to treat PD (6, 7, 268). Below is a summary of dietary interventions that may be useful in the prevention and/or treatment of PD as well as the mechanisms by which this benefit may be conferred on the brain.

Mediterranean Diet as a Treatment

The main components of the Mediterranean diet (MedD) include: daily consumption of vegetables, fruits, nuts, whole grains, and healthy fats; weekly consumption of fish, poultry, beans, and eggs; moderate consumption of dairy products; and limited intake of red meat (10, 124). Adherence to the MedD is associated with decreased risk of PD (9, 269, 270). One of the most dramatic differences between the traditional Western diet and the MedD is dietary fiber intake. Consumption of dietary fiber is typically very low (<10–15 g/day) in Western societies, but high (>25–30 g/day) in those who consume a Mediterranean diet (10, 87–89). It makes sense then that the Mediterranean diet-associated microbiome is characterized by a high relative abundance of bacteria that can utilize fiber as an energy source such as SCFA-producing bacteria (10, 89). Indeed, microbiota communities from subjects consuming a Mediterranean diet are enriched in SCFA-producing bacteria (10, 87, 89, 271). Fiber can also be administered experimentally to alter the microbiota structure and function including an increase in the relative abundance of fiber-fermenting (“good”) bacteria as well as increased production of SCFA (10, 87).

These microbiome changes can elicit a myriad of effects that are beneficial in blunting neuroinflammation and PD pathogenesis. For example, consumption of a high fiber diet improves intestinal barrier function and insulin resistance, improves insulin sensitivity, increases GLP-1/GIP production, stimulates IGN, and increases brain BDNF production (173, 259, 272, 273). Conversely, when fiber consumption is low, the microbiota instead use protein as an energy source which favors the growth of gram negative (LPS-producing, dysbiosis) bacteria and the production of metabolites such as branched chain fatty acids including isovalerate and 2-methyl butyrate that have been associated with insulin resistance (a feature of PD) (274). Fiber consumption (and the consequent production of SCFA) is one mechanism by which the Mediterranean diet may beneficially impact PD development and progression.

In addition to fiber, the Mediterranean diet is also rich in foods that contain anti-oxidant bioflavonoids and polyphenols, which are associated with decreased risk of PD (9, 35, 270). Flavonoids are typically found in fruits, vegetables, grains, and tea. There are not a lot of data available, but it appears that flavonoid consumption also may trigger an increase in SCFA production (36) and several polyphenol bioflavonoids (including in coffee) and fish oil are associated with inhibition of the NLRP3 inflammasome (33, 275). Also, nuts and olive oil stimulate GLP-1 secretion and the MedD after 28 days has been shown to increase GLP-1 production (241).

Taken together there are multiple mechanisms by which the Mediterranean diet can beneficially impact the brain. There is a common theme that components of the Mediterranean diet are especially able to alter the microbiota in a way that promotes SCFA production. SCFA can influence so many PD relevant mechanisms such as barrier function, mitochondrial function, NLRP3, and intestinal peptide production (259, 272, 273) and vagal stimulation of BDNF and thus might be beneficial in PD. However, to date there is no high-quality clinical trial to test the potential benefit of a high fiber Mediterranean diet in PD. These data above provide a strong scientific rationale for conducting randomized controlled dietary trials in PD to determine whether Mediterranean diet can impact neuroinflammation and disease course of PD patients.

Ketogenic Diet and Fasting as a Treatment

It is well-established that caloric restriction and/or intermittent fasting are anti-inflammatory processes and can ameliorate disease in a variety of experimental models, including PD (276, 277). Intermittent fasting is a feeding regimen that cycles between periods of fasting (with either no food or significant caloric restriction), and periods of unrestricted eating. Caloric restriction can improve health, increase lifespan, and improve tolerance to metabolic stresses (278, 279). Indeed, rodents on an intermittent fasting diet exhibit less neuronal dysfunction/degeneration, and fewer PD-like symptoms in models of PD compared to ad libitum-fed controls (280). Similarly, caloric restriction increases levels of neurotrophic factors such as BDNF and attenuates PD-like pathology (including dopaminergic neuron loss) and behavior in rodent and primate models of PD (281, 282) lifestyle interventions such as caloric restriction/fasting and ketogenic diets are currently used to treat epilepsy and other neurological diseases (278, 279). These effects may be due to the fact that ketosis (due to caloric restriction/intermittent fasting, ketogenic diet) increase neurotrophic factors such as BDNF, increases levels of antioxidants, and reduces pro-inflammatory cytokine production (280, 282).

Both fasting and consumption of a ketogenic diet (55–60% fat, 30–35% protein, 5–10% carbohydrate) result in the production of ketone bodies (283). Two metabolic processes are critical in producing energy: gluconeogenesis and ketogenesis. Gluconeogenesis is the endogenous production of glucose in the body primarily from lactic acid, glycerol, and the amino acids alanine and glutamine. When glucose levels are low for prolonged periods (as with fasting), the endogenous production of glucose is not able to keep up with the needs of the body and ketogenesis is primarily used to derive energy (8, 278). Fatty acids and some amino acids are metabolized to form basic ketone bodies which accumulate in the body including: acetoacetate, beta-hydroxybutyrate (BHB), and acetone (8, 278). Ketone bodies may play an important role in mediating the beneficial effects of intermittent fasting and the ketogenic diet on the brain (276).

Ketone bodies are beneficial in humans with PD and animal models of PD. One early study found beneficial effects of hyperketonemia on PD patients (284). Likewise, in a rodent model of PD, BHB is associated with protection against MPTP-induced damage to dopaminergic neurons (285). Furthermore, BHB injection into the brain can rescue mitochondrial function and ameliorate dopaminergic neurodegeneration and motor deficits induced by MPTP in mice (286).

The effects of ketone bodies may be the consequence of a wide variety of mechanisms. For example, ketone bodies can cross the blood brain barrier and may bypass the type 1 complex mitochondrial defect in PD to rescue mitochondrial ATP function (8, 278). Another intriguing potential mechanism is the effects of ketone bodies on the NLRP3 inflammasome (287). For example, fasting can inhibit NLRP3 activation, which is thought to be due to effects of BHB (288, 289). Indeed, BHB directly inhibits the NLRP3 inflammasome and attenuates NLRP3-mediated inflammatory disease (287, 290). Likewise, fasting MPTP mice decreases IL-1β, a marker for NLRP3 activation (218).

In addition to ketone bodies, fasting and consumption of a ketogenic diet can also impact PD pathogenesis by influencing intestinal peptide production (i.e., GLP-1 and GIP) with downstream effects on NLRP3 inflammasome, insulin resistance, and BDNF production (276). Indeed, caloric restriction increases brain BDNF in a primate model of PD (282). Recent studies in MPTP mice shows that fasting increases BDNF in the brain (276).

Also, it appears that fasting impacts normal insulin signaling. Every other day fasting also corrects insulin resistance/T2DM in mice (291). This affect appears to be specific to changes in the intestinal microbiome, including the production of SCFA. Transfer of stool from mice fed every other day into mice with T2DM was sufficient to improve insulin resistance in the recipient mice similar to that observed due to every other day fasting itself (291). Thus, microbiota SCFA, IGN, and/or GLP-1 mediated mechanisms discussed above may play a role in the fasting effects as well. Intermittent fasting also promotes secondary bile acid production and improves intestinal barrier function in mice by restructuring the microbiome to produce more SCFA (292). Finally, ghrelin is another intestinal peptide that is produced in response to fasting and ghrelin is neuroprotective in the PD MPTP model (293). It is thought that the ghrelin protective mechanism may be by promoting mitochondrial health and preventing NLRP3 IL-1β production (293–295).

Collectively, there is evidence that fasting and a ketogenic diet might be beneficial in PD and this effect may be mediated in significant part by changes in the intestinal microbiota. However, once again a well-designed trial is needed to show if the ketogenic diet is beneficial in PD before any serious consideration of fasting/ketogenic diet in the clinical care of PD patients.

Omega 3 Polyunsaturated Fatty Acids

Consumption of PUFAs is also an element of the Mediterranean diet and generally protective against neurodegeneration in AD or PD (296). There are three principal types of omega-3 (ω3) PUFAs including eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA, typically from fish oil), and alpha-linolenic acid (ALA) (296). Dietary supplementation with PUFAs reduces depression in PD patients, which is important because depressive symptoms are common in PD patients and often impact other clinical aspects of the disease (297). In addition, EPA are neuroprotective in several neurodegenerative diseases including PD (6, 18, 298–300). Rodent models of PD also show benefit of PUFA administration. Consumption of an EPA-enriched diet lessens MPTP-induced movement dysfunction (i.e., hypokinesia) and ameliorates memory deficits in mice (298, 301). Administration of DHA reduces 6-OHDA-induced behavior deficits (i.e., ipsilateral rotations) and increases tyrosine hydroxylase (the enzyme required to produce dopamine) levels in a PD rat model (302). Experimentally, DHA is often combined with uridine monophosphate (UMP, a dietary precursor for membrane phospholipid synthesis), the DHA/UMP combination prevents the development of PD-like behavior and pathology in oral and striatal administration of rotenone models (61, 303). In addition, DHA/UMP combination reduces parkinsonian-like behaviors and elevates dopamine levels in 6-OHDA treated rodents (302). There are many mechanisms by which ω3 fatty acids may impact the brain and be beneficial in the prevention and/or treatment of PD. GLP-1 stimulation: As noted above, fish oil and olive oil can stimulate GLP-1/GIP production by the intestine (241). Cell Death: Studies have revealed that supplementation with EPA or DHA attenuates dopaminergic cell death induced by MPTP administration (301, 304). DHA may protect neurons against cytotoxicity through a variety of mechanisms such as inhibition of nitric oxide production, inhibition of caspase signaling pathways (305), inhibition of tau hyperphosphorylation (306), as well as regulation of other signaling pathways (e.g., PI3K/Akt). Cell Function: In addition to inhibiting neuronal cell death, DHA promotes optimal dopaminergic structure and function including synaptic plasticity (synapse formation, dendritic spine density) and dopaminergic neurotransmission (303, 307). Inflammation: The protective effects of DHA may be mediated by a metabolic derivative known as neuroprotectin D1 (NPD1) (308, 309) which is an inhibitor of NLRP3 (310). Indeed, NPD1 protects neurons against oxidative stress, inflammation, and from activation of apoptotic signaling pathways. Thus, while Western diet saturated fats activate the NLRP3 inflammasome (11), consumption of ω3 fatty acids inhibit the NLRP3 inflammasome (including in brain microglia) probably via a mechanism involving reduced mitochondrial stress (311–313). It should not be surprising then that ω3 fatty acids prevent NLRP3 inflammasome-dependent inflammation and insulin resistance in a T2DM rodent model (314). Other: DHA may also protect the brain by increasing glutathione reductase activity essentially preventing protein oxidation (315, 316), lipid peroxidation, and the production of ROS (317). Other potential mechanisms of action of DHA include regulation of NF-κB activation, transcription modulation, and cell membrane properties (318, 319). Again, these data provide a strong scientific rationale for conducting randomized controlled dietary trials in PD to determine whether PUFA supplements can impact neuroinflammation and the disease course of PD patients before recommending it to PD patients.

Conclusion

There is a growing body of experimental in vitro, in vivo animal and epidemiological evidence strongly suggesting that diet impacts the development/progression of multiple neurodegenerative diseases including PD. This includes both beneficial effects of diets rich in fiber, bioflavonoids, and ω3 fatty acids (e.g., the Mediterranean diet), and fasting and the ketogenic diet due the production of ketone bodies as well as the collective detrimental effects of the Western diet that include gut leakiness, NLRP3 activation, insulin resistance, and lack of beneficial SCFA/GLP-1 vagal signaling due to low fiber content. As we have discussed many of these effects may be due in large part to beneficial or negative effects on the intestinal microbiota. Diet rapidly and robustly alters the intestinal microbiome; thus, it is possible that these effects of diet are mediated (at least in part) by changes in microbiota structure and or function.

We described a mechanism by which intestinal dysbiosis can trigger intestinal barrier dysfunction leading to gut-derived LPS with systemic and neuroinflammation. We also described how bacterial components such as LPS can serve as a first signal in NLRP3 inflammasome mediated production of IL-1β, insulin resistance, and mitochondrial dysfunction. Finally, we described how bacterial metabolites such as SCFA and secondary bile acids can directly improve mitochondrial health as well as influence the production of the intestinal peptides GLP-1 and GIP that can directly promote brain health and stimulate IGN and together also regulate vagal stimulation of BDNF in the brain as well.

These data suggest that consumption of a Mediterranean diet might be a useful approach to prevent and possibly treat PD. This is because the characteristic features of the Mediterranean diet including high dietary fiber, bioflavonoids, and ω3 fatty acids that will modulate the microbiome and intestinal cell signaling and result in several alterations that confer benefits in the brain such as improved intestinal and blood brain barrier function, decreased NLRP3 inflammasome activation and IL-1β production, improved insulin sensitivity, increased GLP-1/GIP, IGN vagal stimulation, and increased production of BDNF in the brain. Even if not adhering to the Mediterranean diet, including dietary supplements for dietary fiber, bioflavonoids, or ω3 fatty acids may be beneficial. Similar benefits may be obtained by following a diet involving intermittent fasting or a ketogenic diet.

Further investigations into the mechanisms by which the intestinal microbiota contributes to the development and progression of PD are warranted. More importantly, there is a major unmet need to determine whether dietary intervention can prevent progression of PD from the prodromal phase to the overt CNS/motor phase and whether dietary intervention can modify disease course and disease progression (and response to levodopa treatment) in those who suffer from motor symptoms. We believe that the experimental data and epidemiological findings discussed above provided a strong scientific rationale to conduct well-designed dietary and intestinal microbiota-directed randomized control trials (RCT) in both prodromal and established PD patents.

Author Contributions

All authors contributed significantly to the writing of this review. AJ, CF, AK, RV, PE, and VR wrote the first draft. MS edited the first draft and the final version. All authors edited and approved the final draft. All authors edited and contributed to the final revised resubmission.

Funding

AK would also like to acknowledge philanthropy funding from Mrs. Barbara and Mr. Larry Field, Mrs. Ellen and Mr. Philip Glass, and Mrs. Marcia and Mr. Silas Keehn as well as Department of Defense grant W81XWH-17-1-0587 (to AK).

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2019.01245/full#supplementary-material

References

1. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet. (2009) 373:2055–66. doi: 10.1016/S0140-6736(09)60492-X

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Kalia LV, Lang AE. Parkinson's disease. Lancet. (2015) 386:896–912. doi: 10.1016/S0140-6736(14)61393-3

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Obeso JA, Stamelou M, Goetz CG, Poewe W, Lang AE, Weintraub D, et al. Past, present, future of Parkinson's disease: a special essay on the 200th Anniversary of the Shaking Palsy. Mov Disord. (2017) 32:1264–310. doi: 10.1002/mds.26904

PubMed Abstract | CrossRef Full Text | Google Scholar

4. Marras C, Canning CG, Goldman SM. Environment, lifestyle, Parkinson's disease: Implications for prevention in the next decade. Mov Disord. (2019) 34:801–11. doi: 10.1002/mds.27720

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Seidl SE, Santiago JA, Bilyk H, Potashkin JA. The emerging role of nutrition in Parkinson's disease. Front Aging Neurosci. (2014) 6:36. doi: 10.3389/fnagi.2014.00036

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Perez-Pardo P, Kliest T, Dodiya HB, Broersen LM, Garssen J, Keshavarzian A., Perez-Pardo P, et al. The gut-brain axis in Parkinson's disease: Possibilities for food-based therapies. Eur J Pharmacol. (2017) 817:86–95. doi: 10.1016/j.ejphar.2017.05.042

PubMed Abstract | CrossRef Full Text | Google Scholar

7. Rassmussen H, Piazza BR, Forsyth CB, Keshavarzian A. Nutrition and gastrointestinal health as modulators of Parkinson's disease. In: In: Folkerts G, Garssen J, editors. Pharma-Nutrition. AAPS Advances in the Pharmaceutical Sciences Series. New York, NY: Springer International Publishing (2014). p. 213–42. doi: 10.1007/978-3-319-06151-1_11

CrossRef Full Text | Google Scholar

8. Mattson MP. Interventions that improve body and brain bioenergetics for Parkinson's disease risk reduction and therapy. J Parkinsons Dis. (2014) 4:1–13. doi: 10.3233/JPD-130335

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Mischley LK, Lau RC, Bennett RD. Role of diet and nutritional supplements in Parkinson's disease progression. Oxid Med Cell Longev. (2017) 2017:6405278. doi: 10.1155/2017/6405278

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Makki K, Deehan EC, Walter J, Bäckhed F. The impact of dietary fiber on gut microbiota in host health and disease. Cell Host Microbe. (2018) 23:705–15. doi: 10.1016/j.chom.2018.05.012

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Christ A, Günther P, Lauterbach MAR, Duewell P, Biswas D, Pelka K, et al. Western diet triggers NLRP3-dependent innate immune reprogramming. Cell. (2018) 172:162–75.e14. doi: 10.1016/j.cell.2017.12.013

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Myles IA. Fast food fever: reviewing the impacts of the Western diet on immunity. Nutr J. (2014) 13:61. doi: 10.1186/1475-2891-13-61

PubMed Abstract | CrossRef Full Text | Google Scholar

13. Barichella M, Cereda E, Cassani E, Pinelli G, Iorio L, Ferri V, et al. Dietary habits and neurological features of Parkinson's disease patients: implications for practice. Clin Nutr. (2017) 36:1054–61. doi: 10.1016/j.clnu.2016.06.020

PubMed Abstract | CrossRef Full Text | Google Scholar

14. Liddle RA. Parkinson's disease from the gut. Brain Res. (2018) 1693(Pt B):201–6. doi: 10.1016/j.brainres.2018.01.010

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Anderson C, Checkoway H, Franklin GM, Beresford S, Smith-Weller T, Swanson PD. Dietary factors in Parkinson's disease: the role of food groups and specific foods. Mov Disord. (1999) 14:21–7.

PubMed Abstract | Google Scholar

16. Maraki MI, Yannakoulia M, Stamelou M, Stefanis L, Xiromerisiou G, Kosmidis MH, et al. Mediterranean diet adherence is related to reduced probability of prodromal Parkinson's disease. Mov Disord. (2019) 34:48–57. doi: 10.1002/mds.27489

PubMed Abstract | CrossRef Full Text | Google Scholar

17. Gao X, Cassidy A, Schwarzschild MA, Rimm EB, Ascherio A. Habitual intake of dietary flavonoids and risk of Parkinson disease. Neurology. (2012) 78:1138–45. doi: 10.1212/WNL.0b013e31824f7fc4

PubMed Abstract | CrossRef Full Text | Google Scholar

18. Bousquet M, Calon F, Cicchetti F, Impact of omega-3 fatty acids in Parkinson's disease. Ageing Res Rev. (2011) 10:453–63. doi: 10.1016/j.arr.2011.03.001

CrossRef Full Text | Google Scholar

19. Kamel F, Goldman SM, Umbach DM, Chen H, Richardson G, Barber MR, et al. Dietary fat intake, pesticide use, Parkinson's disease. Parkinsonism Relat Disord. (2013) 20:82–7. doi: 10.1016/j.parkreldis.2013.09.023

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Albenberg LG, Wu GD. Diet and the intestinal microbiome: associations, functions, implications for health and disease. Gastroenterology. (2014) 146:1564–72. doi: 10.1053/j.gastro.2014.01.058

PubMed Abstract | CrossRef Full Text | Google Scholar

21. Heiman ML, Greenway FL. A healthy gastrointestinal microbiome is dependent on dietary diversity. Mol Metab. (2016) 5:317–20. doi: 10.1016/j.molmet.2016.02.005

PubMed Abstract | CrossRef Full Text | Google Scholar

22. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. (2014) 505:559–63. doi: 10.1038/nature12820

PubMed Abstract | CrossRef Full Text | Google Scholar

23. Tremaroli V, Backhed F. Functional interactions between the gut microbiota and host metabolism. Nature. (2012) 489:242–9. doi: 10.1038/nature11552

PubMed Abstract | CrossRef Full Text | Google Scholar

24. Gilbert JA, Blaser MJ, Caporaso JG, Jansson JK, Lynch SV, Knight R. Current understanding of the human microbiome. Nat Med. (2018) 24:392–400. doi: 10.1038/nm.4517

PubMed Abstract | CrossRef Full Text | Google Scholar

25. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. (2011) 334:105–8. doi: 10.1126/science.1208344

PubMed Abstract | CrossRef Full Text | Google Scholar

26. Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA. (2000) 283:2674–9. doi: 10.1001/jama.283.20.2674

PubMed Abstract | CrossRef Full Text | Google Scholar

27. Hernán MA, Takkouche B, Caamaño-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, the risk of Parkinson's disease. Ann Neurol. (2002) 52:276–84. doi: 10.1002/ana.10277

PubMed Abstract | CrossRef Full Text | Google Scholar

28. Tan EK, Tan C, Fook-Chong SM, Lum SY, Chai A, Chung H, et al. Dose-dependent protective effect of coffee, tea, smoking in Parkinson's disease: a study in ethnic Chinese. J Neurol Sci. (2003) 216:163–7. doi: 10.1016/j.jns.2003.07.006

PubMed Abstract | CrossRef Full Text | Google Scholar

29. Kim IY, O'Reilly ÉJ, Hughes KC, Gao X, Schwarzschild MA, Ascherio A. Differences in Parkinson's disease risk with caffeine intake and postmenopausal hormone use. J Parkinsons Dis. (2017) 7:677–84. doi: 10.3233/JPD-171175

PubMed Abstract | CrossRef Full Text | Google Scholar

30. Palacios N, Gao X, McCullough ML, Schwarzschild MA, Shah R, Gapstur S, et al. Caffeine and risk of Parkinson's disease in a large cohort of men and women. Mov Disord. (2012) 27:1276–82. doi: 10.1002/mds.25076

PubMed Abstract | CrossRef Full Text | Google Scholar

31. Maggio R, Riva M, Vaglini F, Fornai F, Molteni R, Armogida M, et al. Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors. J Neurochem. (1998) 71:2439–46. doi: 10.1046/j.1471-4159.1998.71062439.x

PubMed Abstract | CrossRef Full Text | Google Scholar

32. Chen JF, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M, et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci. (2001) 21:RC143. doi: 10.1523/JNEUROSCI.21-10-j0001.2001

PubMed Abstract | CrossRef Full Text | Google Scholar

33. Shi A, Shi H, Wang Y, Liu X, Cheng Y, Li H, et al. Activation of Nrf2 pathway and inhibition of NLRP3 inflammasome activation contribute to the protective effect of chlorogenic acid on acute liver injury. Int Immunopharmacol. (2018) 54:125–30. doi: 10.1016/j.intimp.2017.11.007

PubMed Abstract | CrossRef Full Text | Google Scholar

34. Yan R, Zhang J, Park HJ, Park ES, Oh S, Zheng H, et al. Synergistic neuroprotection by coffee components eicosanoyl-5-hydroxytryptamide and caffeine in models of Parkinson's disease and DLB. Proc Natl Acad Sci USA. (2018) 115:E12053–62. doi: 10.1073/pnas.1813365115

PubMed Abstract | CrossRef Full Text | Google Scholar

35. Kujawska M, Jodynis-Liebert J. Polyphenols in Parkinson's disease: a systematic review of in vivo studies. Nutrients. (2018) 10:E642. doi: 10.3390/nu10050642

PubMed Abstract | CrossRef Full Text | Google Scholar

36. Hanhineva K, Törrönen R, Bondia-Pons I, Pekkinen J, Kolehmainen M, Mykkänen H, et al. Impact of dietary polyphenols on carbohydrate metabolism. Int J Mol Sci. (2010) 11:1365–402. doi: 10.3390/ijms11041365

PubMed Abstract | CrossRef Full Text | Google Scholar

37. Derkinderen P, Shannon KM, Brundin P. Gut feelings about smoking and coffee in Parkinson's disease. Mov Disord. (2014) 29:976–9. doi: 10.1002/mds.25882

PubMed Abstract | CrossRef Full Text | Google Scholar

38. Scheperjans F, Pekkonen E, Kaakkola S, Auvinen P. Linking smoking, coffee, urate, Parkinson's disease - A role for gut microbiota? J Parkinsons Dis. (2015) 5:255–62. doi: 10.3233/JPD-150557

PubMed Abstract | CrossRef Full Text | Google Scholar

39. Palacios N, Gao X, O'Reilly E, Schwarzschild M, McCullough ML, Mayo T, et al. Alcohol and risk of Parkinson's disease in a large, prospective cohort of men and women. Mov Disord. (2012) 27:980–7. doi: 10.1002/mds.25050

PubMed Abstract | CrossRef Full Text | Google Scholar

40. Hernán MA, Chen H, Schwarzschild MA, Ascherio A. Alcohol consumption and the incidence of Parkinson's disease. Ann Neurol. (2003) 54:170–5. doi: 10.1002/ana.10611

PubMed Abstract | CrossRef Full Text | Google Scholar

41. Ishihara L, Brayne C. A systematic review of nutritional risk factors of Parkinson's disease. Nutr Res Rev. (2005) 18:259–82. doi: 10.1079/NRR2005108

PubMed Abstract | CrossRef Full Text | Google Scholar

42. Brighina L, Schneider NK, Lesnick TG, de Andrade M, Cunningham JM, Mrazek D., Brighina L, et al. Alpha-synuclein, alcohol use disorders, Parkinson disease: a case-control study. Parkinsonism Relat Disord. (2009) 15:430–4. doi: 10.1016/j.parkreldis.2008.11.011

CrossRef Full Text | Google Scholar

43. Bettiol SS, Rose TC, Hughes CJ, Smith LA. Alcohol consumption and Parkinson's disease risk: A review of recent findings. J Parkinsons Dis. (2015) 5:425–42. doi: 10.3233/JPD-150533

PubMed Abstract | CrossRef Full Text | Google Scholar

44. Hillemacher T, Bachmann O, Kahl KG, Frieling H. Alcohol, microbiome, their effect on psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. (2018) 85:105–15. doi: 10.1016/j.pnpbp.2018.04.015

PubMed Abstract | CrossRef Full Text | Google Scholar

45. Mutlu EA, Gillevet PM, Rangwala H, Sikaroodi M, Naqvi A, Engen PA, et al. Colonic microbiome is altered in alcoholism. Am J Physiol Gastrointest Liver Physiol. (2012) 302:G966–78. doi: 10.1152/ajpgi.00380.2011

PubMed Abstract | CrossRef Full Text | Google Scholar

46. Engen PA, Green SJ, Voigt RM, Forsyth CB, Keshavarzian A. The gastrointestinal microbiome: alcohol effects on the composition of intestinal microbiota. Alcohol Res. (2015) 37:223–36.

PubMed Abstract | Google Scholar

47. Chen H, O'Reilly E, McCullough ML, Rodriguez C, Schwarzschild MA, Calle EE, et al. Consumption of dairy products and risk of Parkinson's disease. Am J Epidemiol. (2007) 165:998–1006. doi: 10.1093/aje/kwk089

PubMed Abstract | CrossRef Full Text | Google Scholar

48. Chen H, Zhang SM, Hernán MA, Willett WC, Ascherio A. Diet and Parkinson's disease: a potential role of dairy products in men. Ann Neurol. (2002) 52:793–801. doi: 10.1002/ana.10381

PubMed Abstract | CrossRef Full Text | Google Scholar

49. Park M, Ross GW, Petrovitch H, White LR, Masaki KH, Nelson JS, et al. Consumption of milk and calcium in midlife and the future risk of Parkinson disease. Neurology. (2005) 64:1047–51. doi: 10.1212/01.WNL.0000154532.98495.BF

PubMed Abstract | CrossRef Full Text | Google Scholar

50. Kyrozis A, Ghika A, Stathopoulos P, Vassilopoulos D, Trichopoulos D, Trichopoulou A. Dietary and lifestyle variables in relation to incidence of Parkinson's disease in Greece. Eur J Epidemiol. (2013) 28:67–77. doi: 10.1007/s10654-012-9760-0

PubMed Abstract | CrossRef Full Text | Google Scholar

51. Hughes KC, Gao X, Kim IY, Wang M, Weisskopf MG, Schwarzschild MA, et al. Intake of dairy foods and risk of Parkinson disease. Neurology. (2017) 89:46–52. doi: 10.1212/WNL.0000000000004057

PubMed Abstract | CrossRef Full Text | Google Scholar

52. Jiang W, Ju C, Jiang H, Zhang D. Dairy foods intake and risk of Parkinson's disease: a dose-response meta-analysis of prospective cohort studies. Eur J Epidemiol. (2014) 29:613–9. doi: 10.1007/s10654-014-9921-4

PubMed Abstract | CrossRef Full Text | Google Scholar

53. Abbott RD, Ross GW, Petrovitch H, Masaki KH, Launer LJ, Nelson JS, et al. Midlife milk consumption and substantia nigra neuron density at death. Neurology. (2016) 86:512–9. doi: 10.1212/WNL.0000000000002254

PubMed Abstract | CrossRef Full Text | Google Scholar

54. Tetz G, Brown SM, Hao Y, Tetz V. Parkinson's disease and bacteriophages as its overlooked contributors. Sci Rep. (2018) 8:10812. doi: 10.1038/s41598-018-29173-4

PubMed Abstract | CrossRef Full Text | Google Scholar

55. Kistner A, Krack P. Parkinson's disease: no milk today? Front Neurol. (2014) 5:172. doi: 10.3389/fneur.2014.00172

PubMed Abstract | CrossRef Full Text | Google Scholar

56. Hatcher JM, Pennell KD, Miller GW. Parkinson's disease and pesticides: a toxicological perspective. Trends Pharmacol Sci. (2008) 29:322–9. doi: 10.1016/j.tips.2008.03.007

PubMed Abstract | CrossRef Full Text | Google Scholar

57. Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, et al. Rotenone, paraquat, Parkinson's disease. Environ Health Perspect. (2011) 119:866–72. doi: 10.1289/ehp.1002839

PubMed Abstract | CrossRef Full Text | Google Scholar

58. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem. (1990) 54:823–7. doi: 10.1111/j.1471-4159.1990.tb02325.x

PubMed Abstract | CrossRef Full Text | Google Scholar

59. Zhu J, Chu CT, Mitochondrial dysfunction in Parkinson's disease. J Alzheimers Dis. (2010) 20(Suppl. 2):S325–34. doi: 10.3233/JAD-2010-100363

CrossRef Full Text | Google Scholar

60. Salminen A, Ojala J, Kaarniranta K, Kauppinen A. Mitochondrial dysfunction and oxidative stress activate inflammasomes: impact on the aging process and age-related diseases. Cell Mol Life Sci. (2012) 69:2999–3013. doi: 10.1007/s00018-012-0962-0

PubMed Abstract | CrossRef Full Text | Google Scholar

61. Perez-Pardo P, Dodiya HB, Broersen LM, Douna H, van Wijk N, Lopes da Silva S, et al. Gut-brain and brain-gut axis in Parkinson's disease models: effects of a uridine and fish oil diet. Nutr Neurosci. (2017) 21:391–402. doi: 10.1080/1028415X.2017.1294555

PubMed Abstract | CrossRef Full Text | Google Scholar

62. Greenamyre JT, Cannon JR, Drolet R, Mastroberardino PG. Lessons from the rotenone model of Parkinson's disease. Trends Pharmacol Sci. (2010) 31:141–2; author reply:142–3. doi: 10.1016/j.tips.2009.12.006

PubMed Abstract | CrossRef Full Text | Google Scholar

63. Langston JW. The MPTP story. J Parkinsons Dis. (2017) 7:S11–9. doi: 10.3233/JPD-179006

PubMed Abstract | CrossRef Full Text | Google Scholar

64. Cicchetti F, Drouin-Ouellet J, Gross RE. Environmental toxins and Parkinson's disease: what have we learned from pesticide-induced animal models? Trends Pharmacol Sci. (2009) 30:475–83. doi: 10.1016/j.tips.2009.06.005

PubMed Abstract | CrossRef Full Text | Google Scholar

65. Priyadarshi A, Khuder SA, Schaub EA, Shrivastava S. A meta-analysis of Parkinson's disease and exposure to pesticides. Neurotoxicology. (2000) 21:435–40.

PubMed Abstract | Google Scholar

66. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. (1983) 219:979–80. doi: 10.1126/science.6823561

PubMed Abstract | CrossRef Full Text | Google Scholar

67. Ascherio A, Chen H, Weisskopf MG, O'Reilly E, McCullough ML, Calle EE, et al. Pesticide exposure and risk for Parkinson's disease. Ann Neurol. (2006) 60:197–203. doi: 10.1002/ana.20904

PubMed Abstract | CrossRef Full Text | Google Scholar

68. Perez-Pardo P, Dodiya HB, Engen PA, Forsyth CB, Huschens AM, Shaikh M, et al. Role of TLR4 in the gut-brain axis in Parkinson's disease: a translational study from men to mice. Gut. (2018) 68:829–43. doi: 10.1136/gutjnl-2018-316844

PubMed Abstract | CrossRef Full Text | Google Scholar

69. Perez-Pardo P, Dodiya HB, Engen PA, Naqib A, Forsyth CB, Green SJ, et al. Gut bacterial composition in a mouse model of Parkinson's disease. Benef Microbes. (2018) 9:799–814. doi: 10.3920/BM2017.0202

PubMed Abstract | CrossRef Full Text | Google Scholar

70. Johnson ME, Stringer A, Bobrovskaya L. Rotenone induces gastrointestinal pathology and microbiota alterations in a rat model of Parkinson's disease. Neurotoxicology. (2018) 65:174–85. doi: 10.1016/j.neuro.2018.02.013

PubMed Abstract | CrossRef Full Text | Google Scholar

71. Gao B, Bian X, Chi L, Tu P, Ru H, Lu K. Editor's highlight: organophosphatediazinon altered quorum sensing, cell motility, stress response, carbohydrate metabolism of gut microbiome. Toxicol Sci. (2017) 157:354–64. doi: 10.1093/toxsci/kfx053

PubMed Abstract | CrossRef Full Text | Google Scholar

72. Killinger BA, Labrie V. Vertebrate food products as a potential source of prion-like alpha-synuclein. NPJ Parkinsons Dis. (2017) 3:33. doi: 10.1038/s41531-017-0035-z

PubMed Abstract | CrossRef Full Text | Google Scholar

73. Uversky VN, Eliezer D. Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein. Curr Protein Pept Sci. (2009) 10:483–99. doi: 10.2174/138920309789351921

PubMed Abstract | CrossRef Full Text | Google Scholar

74. Stefanis L. alpha-Synuclein in Parkinson's disease. Cold Spring Harb Perspect Med. (2012) 2:a009399. doi: 10.1101/cshperspect.a009399

PubMed Abstract | CrossRef Full Text | Google Scholar

75. Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, Lee VM. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med. (2012) 209:975–86. doi: 10.1084/jem.20112457

PubMed Abstract | CrossRef Full Text | Google Scholar

76. Luk KC, Song C, O'Brien P, Stieber A, Branch JR, Brunden KR, et al. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci USA. (2009) 106:20051–6. doi: 10.1073/pnas.0908005106

PubMed Abstract | CrossRef Full Text | Google Scholar

77. Gordon R, Albornoz EA, Christie DC, Langley MR, Kumar V, Mantovani S, et al. Inflammasome inhibition prevents alpha-synuclein pathology and dopaminergic neurodegeneration in mice. Sci Transl Med. (2018) 10:eaah4066. doi: 10.1126/scitranslmed.aah4066

PubMed Abstract | CrossRef Full Text | Google Scholar

78. Peelaerts W, Bousset L, Van der Perren A, Moskalyuk A, Pulizzi R, Giugliano M, et al. alpha-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature. (2015) 522:340–4. doi: 10.1038/nature14547

PubMed Abstract | CrossRef Full Text | Google Scholar

79. Rota L, Pellegrini C, Benvenuti L, Antonioli L, Fornai M, Blandizzi C, et al. Constipation, deficit in colon contractions and alpha-synuclein inclusions within the colon precede motor abnormalities and neurodegeneration in the central nervous system in a mouse model of alpha-synucleinopathy. Transl Neurodegener. (2019) 8:5. doi: 10.1186/s40035-019-0146-z

PubMed Abstract | CrossRef Full Text | Google Scholar

80. Kim S, Kwon SH, Kam TI, Panicker N, Karuppagounder SS, Lee S, et al. Transneuronal propagation of pathologic alpha-synuclein from the gut to the brain models Parkinson's disease. Neuron. (2019) 103:627–41.e7. doi: 10.1016/j.neuron.2019.05.035

PubMed Abstract | CrossRef Full Text | Google Scholar

81. Holmqvist S, Chutna O, Bousset L, Aldrin-Kirk P, Li W, Björklund T, et al. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol. (2014) 128:805–20. doi: 10.1007/s00401-014-1343-6

PubMed Abstract | CrossRef Full Text | Google Scholar

82. Donaldson DS, Kobayashi A, Ohno H, Yagita H, Williams IR, Mabbott NA. M cell-depletion blocks oral prion disease pathogenesis. Mucosal Immunol. (2012) 5:216–25. doi: 10.1038/mi.2011.68

PubMed Abstract | CrossRef Full Text | Google Scholar

83. Wood H. Parkinson disease: LAG3 facilitates cell-to-cell spread of alpha-synuclein pathology. Nat Rev Neurol. (2016) 12:678. doi: 10.1038/nrneurol.2016.164

PubMed Abstract | CrossRef Full Text | Google Scholar

84. Forsyth CB, Shannon KM, Kordower JH, Voigt RM, Shaikh M, Jaglin JA, et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS ONE. (2011) 6:e28032. doi: 10.1371/journal.pone.0028032

PubMed Abstract | CrossRef Full Text | Google Scholar

85. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. (2012) 486:207–14. doi: 10.1038/nature11234

CrossRef Full Text | Google Scholar

86. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. (2010) 464:59–65. doi: 10.1038/nature08821

PubMed Abstract | CrossRef Full Text | Google Scholar

87. Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. (2016) 165:1332–45. doi: 10.1016/j.cell.2016.05.041

PubMed Abstract | CrossRef Full Text | Google Scholar

88. Deehan EC, Duar RM, Armet AM, Perez-Muñoz ME, Jin M, Walter J. Modulation of the gastrointestinal microbiome with nondigestible fermentable carbohydrates to improve human health. Microbiol Spectr. (2017) 5:1–24. doi: 10.1128/microbiolspec.BAD-0019-2017

PubMed Abstract | CrossRef Full Text | Google Scholar

89. Garcia-Mantrana I, Selma-Royo M, Alcantara C, Collado MC. Shifts on gut microbiota associated to mediterranean diet adherence and specific dietary intakes on general adult population. Front Microbiol. (2018) 9:890. doi: 10.3389/fmicb.2018.00890

PubMed Abstract | CrossRef Full Text | Google Scholar

90. Gilbert JA, Quinn RA, Debelius J, Xu ZZ, Morton J, Garg N, et al. Microbiome-wide association studies link dynamic microbial consortia to disease. Nature. (2016) 535:94–103. doi: 10.1038/nature18850

PubMed Abstract | CrossRef Full Text | Google Scholar

91. Buford TW. (Dis)Trust your gut: the gut microbiome in age-related inflammation, health, disease. Microbiome. (2017) 5:80. doi: 10.1186/s40168-017-0296-0

PubMed Abstract | CrossRef Full Text | Google Scholar

92. Clemente JC, Ursell LK, Parfrey LW, Knight R. The impact of the gut microbiota on human health: an integrative view. Cell. (2012) 148:1258–70. doi: 10.1016/j.cell.2012.01.035

PubMed Abstract | CrossRef Full Text | Google Scholar

93. Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat Rev Genet. (2012) 13:260–70. doi: 10.1038/nrg3182

PubMed Abstract | CrossRef Full Text | Google Scholar

94. Bell JS, Spencer JI, Yates RL, Yee SA, Jacobs BM, DeLuca GC. Invited review: from nose to gut - the role of the microbiome in neurological disease. Neuropathol Appl Neurobiol. (2019) 45:195–215. doi: 10.1111/nan.12520

PubMed Abstract | CrossRef Full Text | Google Scholar

95. Lubomski M, Tan AH, Lim SY, Holmes AJ, Davis RL, Sue CM. Parkinson's disease and the gastrointestinal microbiome. J Neurol. (2019) 91:1–17. doi: 10.1007/s00415-019-09320-1

CrossRef Full Text | Google Scholar

96. Sampson T. The impact of indigenous microbes on Parkinson's disease. Neurobiol Dis. (2019) 104426. doi: 10.1016/j.nbd.2019.03.014

PubMed Abstract | CrossRef Full Text | Google Scholar

97. Scheperjans F, Aho V, Pereira PA, Koskinen K, Paulin L, Pekkonen E, et al. Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov Disord. (2014) 30:350–8. doi: 10.1002/mds.26069

PubMed Abstract | CrossRef Full Text | Google Scholar

98. Keshavarzian A, Green SJ, Engen PA, Voigt RM, Naqib A, Forsyth CB, et al. Colonic bacterial composition in Parkinson's disease. Mov Disord. (2015) 30:1351–60. doi: 10.1002/mds.26307

PubMed Abstract | CrossRef Full Text | Google Scholar

99. Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature. (2012) 489:220–30. doi: 10.1038/nature11550

PubMed Abstract | CrossRef Full Text | Google Scholar

100. Caporaso JG, Lauber CL, Costello EK, Berg-Lyons D, Gonzalez A, Stombaugh J, et al. Moving pictures of the human microbiome. Genome Biol. (2011) 12:R50. doi: 10.1186/gb-2011-12-5-r50

PubMed Abstract | CrossRef Full Text | Google Scholar

101. Noble EE, Hsu TM, Kanoski SE. Gut to brain dysbiosis: mechanisms linking western diet consumption, the microbiome, cognitive impairment. Front Behav Neurosci. (2017) 11:9. doi: 10.3389/fnbeh.2017.00009

PubMed Abstract | CrossRef Full Text | Google Scholar

102. Miller GE, Engen PA, Gillevet PM, Shaikh M, Sikaroodi M, Forsyth CB, et al. Lower neighborhood socioeconomic status associated with reduced diversity of the colonic microbiota in healthy adults. PLoS ONE. (2016) 11:e0148952. doi: 10.1371/journal.pone.0148952

PubMed Abstract | CrossRef Full Text | Google Scholar

103. Aho VTE, Pereira PAB, Voutilainen S, Paulin L, Pekkonen E, Auvinen P, et al. Gut microbiota in Parkinson's disease: temporal stability and relations to disease progression. EBioMedicine. (2019) 44:691–707. doi: 10.1016/j.ebiom.2019.05.064

PubMed Abstract | CrossRef Full Text | Google Scholar

104. Minato T, Maeda T, Fujisawa Y, Tsuji H, Nomoto K, Ohno K, et al. Progression of Parkinson's disease is associated with gut dysbiosis: Two-year follow-up study. PLoS ONE. (2017) 12:e0187307. doi: 10.1371/journal.pone.0187307

PubMed Abstract | CrossRef Full Text | Google Scholar

105. Heintz-Buschart A, Pandey U, Wicke T, Sixel-Döring F, Janzen A, Sittig-Wiegand E, et al. The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder. Mov Disord. (2018) 33:88–98. doi: 10.1002/mds.27105

PubMed Abstract | CrossRef Full Text | Google Scholar

106. Mihaila D, Donegan J, Barns S, LaRocca D, Du Q, Zheng D, et al. The oral microbiome of early stage Parkinson's disease and its relationship with functional measures of motor and non-motor function. PLoS ONE. (2019) 14:e0218252. doi: 10.1371/journal.pone.0218252

PubMed Abstract | CrossRef Full Text | Google Scholar

107. Pereira PAB, Aho VTE, Paulin L, Pekkonen E, Auvinen P, Scheperjans F. Oral and nasal microbiota in Parkinson's disease. Parkinsonism Relat Disord. (2017) 38:61–7. doi: 10.1016/j.parkreldis.2017.02.026

PubMed Abstract | CrossRef Full Text | Google Scholar

108. Unger MM, Spiegel J, Dillmann KU, Grundmann D, Philippeit H, Bürmann J, et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls. Parkinsonism Relat Disord. (2016) 32:66–72. doi: 10.1016/j.parkreldis.2016.08.019

PubMed Abstract | CrossRef Full Text | Google Scholar

109. Bedarf JR, Hildebrand F, Coelho LP, Sunagawa S, Bahram M, Goeser F, et al. Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naive Parkinson's disease patients. Genome Med. (2017) 9:39. doi: 10.1186/s13073-017-0451-z

CrossRef Full Text | Google Scholar

110. Hill-Burns EM, Debelius JW, Morton JT, Wissemann WT, Lewis MR, Wallen ZD, et al. Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome. Mov Disord. (2017) 32:739–49. doi: 10.1002/mds.26942

PubMed Abstract | CrossRef Full Text | Google Scholar

111. Barichella M, Severgnini M, Cilia R, Cassani E, Bolliri C, Caronni S, et al. Unraveling gut microbiota in Parkinson's disease and atypical Parkinsonism. Mov Disord. (2019) 34:396–405. doi: 10.1002/mds.27581

PubMed Abstract | CrossRef Full Text | Google Scholar

112. Li C, Cui L, Yang Y, Miao J, Zhao X, Zhang J, et al. Gut microbiota differs between Parkinson's disease patients and healthy controls in northeast China. Front Mol Neurosci. (2019) 12:171. doi: 10.3389/fnmol.2019.00171

PubMed Abstract | CrossRef Full Text | Google Scholar

113. Petrov VA, Saltykova IV, Zhukova IA, Alifirova VM, Zhukova NG, Dorofeeva YB, et al. Analysis of gut microbiota in patients with Parkinson's disease. Bull Exp Biol Med. (2017) 162:734–7. doi: 10.1007/s10517-017-3700-7

PubMed Abstract | CrossRef Full Text | Google Scholar

114. Lin A, Zheng W, He Y, Tang W, Wei X, He R, et al. Gut microbiota in patients with Parkinson's disease in southern China. Parkinsonism Relat Disord. (2018) 53:82–8. doi: 10.1016/j.parkreldis.2018.05.007

PubMed Abstract | CrossRef Full Text | Google Scholar

115. Hasegawa S, Goto S, Tsuji H, Okuno T, Asahara T, Nomoto K, et al. Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson's disease. PLoS ONE. (2015) 10:e0142164. doi: 10.1371/journal.pone.0142164

PubMed Abstract | CrossRef Full Text | Google Scholar

116. Hopfner F, Künstner A, Müller SH, Künzel S, Zeuner KE, Margraf NG, et al. Gut microbiota in Parkinson disease in a northern German cohort. Brain Res. (2017) 1667:41–5. doi: 10.1016/j.brainres.2017.04.019

PubMed Abstract | CrossRef Full Text | Google Scholar

117. Li W, Wu X, Hu X, Wang T, Liang S, Duan Y, et al. Structural changes of gut microbiota in Parkinson's disease and its correlation with clinical features. Sci China Life Sci. (2017) 60:1223–33. doi: 10.1007/s11427-016-9001-4

PubMed Abstract | CrossRef Full Text | Google Scholar

118. Langille MG, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA, et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol. (2013) 31:814–21. doi: 10.1038/nbt.2676

PubMed Abstract | CrossRef Full Text | Google Scholar

119. Qian Y, Yang X, Xu S, Wu C, Song Y, Qin N, et al. Alteration of the fecal microbiota in Chinese patients with Parkinson's disease. Brain Behav Immun. (2018) 70:194–202. doi: 10.1016/j.bbi.2018.02.016

PubMed Abstract | CrossRef Full Text | Google Scholar

120. Braak H, Rüb U, Gai WP, Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm. (2003) 110:517–36. doi: 10.1007/s00702-002-0808-2

PubMed Abstract | CrossRef Full Text | Google Scholar

121. Hawkes CH, Del Tredici K, Braak H. Parkinson's disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol. (2007) 33:599–614. doi: 10.1111/j.1365-2990.2007.00874.x

PubMed Abstract | CrossRef Full Text | Google Scholar

122. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Parkinsonism Relat Disord. (2011) 17:10–5. doi: 10.1016/j.parkreldis.2010.08.003

PubMed Abstract | CrossRef Full Text | Google Scholar

123. Fasano A, Visanji NP, Liu LW, Lang AE, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol. (2015) 14:625–39. doi: 10.1016/S1474-4422(15)00007-1

PubMed Abstract | CrossRef Full Text | Google Scholar

124. Cassani E, Barichella M, Ferri V, Pinelli G, Iorio L, Bolliri C, et al. Dietary habits in Parkinson's disease: adherence to Mediterranean diet. Parkinsonism Relat Disord. (2017) 42:40–6. doi: 10.1016/j.parkreldis.2017.06.007

PubMed Abstract | CrossRef Full Text | Google Scholar

125. Zhou ZL, Jia XB, Sun MF, Zhu YL, Qiao CM, Zhang BP, et al. Neuroprotection of fasting mimicking diet on MPTP-induced Parkinson's disease mice via gut microbiota and metabolites. Neurotherapeutics. (2019) 16:741–60. doi: 10.1007/s13311-019-00719-2

PubMed Abstract | CrossRef Full Text | Google Scholar

126. Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD, et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology. (2001) 57:456–62. doi: 10.1212/WNL.57.3.456

PubMed Abstract | CrossRef Full Text | Google Scholar

127. Knudsen K, Krogh K, Østergaard K, Borghammer P. Constipation in Parkinson's disease: subjective symptoms, objective markers, new perspectives. Mov Disord. (2017) 32:94–105. doi: 10.1002/mds.26866

PubMed Abstract | CrossRef Full Text | Google Scholar

128. Khalif IL, Quigley EM, Konovitch EA, Maximova ID. Alterations in the colonic flora and intestinal permeability and evidence of immune activation in chronic constipation. Dig Liver Dis. (2005) 37:838–49. doi: 10.1016/j.dld.2005.06.008

PubMed Abstract | CrossRef Full Text | Google Scholar

129. Videnovic A, Golombek D. Circadian and sleep disorders in Parkinson's disease. Exp Neurol. (2013) 243:45–56. doi: 10.1016/j.expneurol.2012.08.018

PubMed Abstract | CrossRef Full Text | Google Scholar

130. Videnovic A, Willis GL. Circadian system - A novel diagnostic and therapeutic target in Parkinson's disease? Mov Disord. (2016) 31:260–9. doi: 10.1002/mds.26509

PubMed Abstract | CrossRef Full Text | Google Scholar

131. Voigt RM, Forsyth CB, Green SJ, Engen PA, Keshavarzian A. Circadian rhythm and the gut microbiome. Int Rev Neurobiol. (2016) 131:193–205. doi: 10.1016/bs.irn.2016.07.002

PubMed Abstract | CrossRef Full Text | Google Scholar

132. Paschos GK, FitzGerald GA. Circadian clocks and metabolism: implications for microbiome and aging. Trends Genet. (2017) 33:760–9. doi: 10.1016/j.tig.2017.07.010

PubMed Abstract | CrossRef Full Text | Google Scholar

133. Scheperjans F, Derkinderen P, Borghammer P. The gut and Parkinson's disease: hype or hope? J Parkinsons Dis. (2018) 8:S31–9. doi: 10.3233/JPD-181477

CrossRef Full Text | Google Scholar

134. Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell. (2016) 167:1469–80.e12. doi: 10.1016/j.cell.2016.11.018

PubMed Abstract | CrossRef Full Text | Google Scholar

135. Austin KW, Ameringer SW, Cloud LJ. An integrated review of psychological stress in Parkinson's disease: biological mechanisms and symptom and health outcomes. Parkinsons Dis. (2016) 2016:9869712. doi: 10.1155/2016/9869712

PubMed Abstract | CrossRef Full Text | Google Scholar

136. Chen H, Ritz B. The search for environmental causes of Parkinson's disease: moving forward. J Parkinsons Dis. (2018) 8:S9–17. doi: 10.3233/JPD-181493

PubMed Abstract | CrossRef Full Text | Google Scholar

137. Dodiya HB, Forsyth CB, Voigt RM, Engen PA, Patel J, Shaikh M, et al. Chronic stress-induced gut dysfunction exacerbates Parkinson's disease phenotype and pathology in a rotenone-induced mouse model of Parkinson's disease. Neurobiol Dis. (2018) 104352. doi: 10.1016/j.nbd.2018.12.012

PubMed Abstract | CrossRef Full Text | Google Scholar

138. Allen JM, Mailing LJ, Niemiro GM, Moore R, Cook MD, White BA, et al. Exercise alters gut microbiota composition and function in lean and obese humans. Med Sci Sports Exerc. (2018) 50:747–57. doi: 10.1249/MSS.0000000000001495

PubMed Abstract | CrossRef Full Text | Google Scholar

139. Borghammer P. How does Parkinson's disease begin? Perspectives on neuroanatomical pathways, prions, histology. Mov Disord. (2018) 33:48–57. doi: 10.1002/mds.27138

PubMed Abstract | CrossRef Full Text | Google Scholar

140. Lionnet A, Leclair-Visonneau L, Neunlist M, Murayama S, Takao M, Adler CH, et al. Does Parkinson's disease start in the gut? Acta Neuropathol. (2017) 135:1–12. doi: 10.1007/s00401-017-1777-8

PubMed Abstract | CrossRef Full Text | Google Scholar

141. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci USA. (2009) 106:13010–5. doi: 10.1073/pnas.0903691106

PubMed Abstract | CrossRef Full Text | Google Scholar

142. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med. (2008) 14:504–6. doi: 10.1038/nm1747

PubMed Abstract | CrossRef Full Text | Google Scholar

143. Kordower JH, Chu Y, Hauser RA, Olanow CW, Freeman TB. Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord. (2008) 23:2303–6. doi: 10.1002/mds.22369

PubMed Abstract | CrossRef Full Text | Google Scholar

144. Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med. (2008) 14:501–3. doi: 10.1038/nm1746

PubMed Abstract | CrossRef Full Text | Google Scholar

145. Kujawska M, Jodynis-Liebert J. What is the evidence that Parkinson's disease is a prion disorder, which originates in the gut? Int J Mol Sci. (2018) 19:E3573. doi: 10.3390/ijms19113573

PubMed Abstract | CrossRef Full Text | Google Scholar

146. Riederer P, Berg D, Casadei N, Cheng F, Classen J, Dresel C, et al. α-synuclein in Parkinson's disease: causal or bystander? J Neural Transm. (2019) 126:815–40. doi: 10.1007/s00702-019-02025-9

CrossRef Full Text | Google Scholar

147. Santos SF, de Oliveira HL, Yamada ES, Neves BC, Pereira A. The gut and Parkinson's disease-a bidirectional pathway. Front Neurol. (2019) 10:574. doi: 10.3389/fneur.2019.00574

PubMed Abstract | CrossRef Full Text | Google Scholar

148. Perez-Pardo P, Hartog M, Garssen J, Kraneveld AD. Microbes tickling your tummy: the importance of the gut-brain axis in Parkinson's Disease. Curr Behav Neurosci Rep. (2017) 4:361–8. doi: 10.1007/s40473-017-0129-2

PubMed Abstract | CrossRef Full Text | Google Scholar

149. Dutta G, Zhang P, Liu B. The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery. Fundam Clin Pharmacol. (2008) 22:453–64. doi: 10.1111/j.1472-8206.2008.00616.x

PubMed Abstract | CrossRef Full Text | Google Scholar

150. Zhao Y, Jaber V, Lukiw WJ. Secretory products of the human GI tract microbiome and their potential impact on Alzheimer's disease (AD): detection of lipopolysaccharide (LPS) in AD hippocampus. Front Cell Infect Microbiol. (2017) 7:318. doi: 10.3389/fcimb.2017.00318

PubMed Abstract | CrossRef Full Text | Google Scholar

151. Sampson TR, Mazmanian SK. Control of brain development, function, behavior by the microbiome. Cell Host Microbe. (2015) 17:565–76. doi: 10.1016/j.chom.2015.04.011

PubMed Abstract | CrossRef Full Text | Google Scholar

152. Bourassa MW, Alim I, Bultman SJ, Ratan RR. Butyrate, neuroepigenetics and the gut microbiome: Can a high fiber diet improve brain health? Neurosci Lett. (2016) 625:56–63. doi: 10.1016/j.neulet.2016.02.009

PubMed Abstract | CrossRef Full Text | Google Scholar

153. Dinan TG, Cryan JF. Gut feelings on Parkinson's and depression. Cerebrum. (2017) 2017:cer-04-17.

PubMed Abstract | Google Scholar

154. Everard A, Cani PD. Gut microbiota and GLP-1. Rev Endocr Metab Disord. (2014) 15:189–96. doi: 10.1007/s11154-014-9288-6

PubMed Abstract | CrossRef Full Text | Google Scholar

155. Liu J, Wang F, Liu S, Du J, Hu X, Xiong J, et al. Sodium butyrate exerts protective effect against Parkinson's disease in mice via stimulation of glucagon like peptide-1. J Neurol Sci. (2017) 381:176–81. doi: 10.1016/j.jns.2017.08.3235

PubMed Abstract | CrossRef Full Text | Google Scholar

156. Shannon KM, Keshavarzian A, Dodiya HB, Jakate S, Kordower JH. Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov Disord. (2012) 27:716–9. doi: 10.1002/mds.25020

PubMed Abstract | CrossRef Full Text | Google Scholar

157. Shannon KM, Keshavarzian A, Mutlu E, Dodiya HB, Daian D, Jaglin JA, et al. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord. (2012) 27:709–15. doi: 10.1002/mds.23838

PubMed Abstract | CrossRef Full Text | Google Scholar

158. Lebouvier T, Chaumette T, Paillusson S, Duyckaerts C, Bruley des Varannes S, Neunlist M, et al. The second brain and Parkinson' disease. Eur J Neurosci. (2009) 30:735–41. doi: 10.1111/j.1460-9568.2009.06873.x

CrossRef Full Text | Google Scholar

159. Ruffmann C, Parkkinen L. Gut feelings about alpha-synuclein in gastrointestinal biopsies: biomarker in the making? Mov Disord. (2016) 31:193–202. doi: 10.1002/mds.26480

PubMed Abstract | CrossRef Full Text | Google Scholar

160. Stokholm MG, Danielsen EH, Hamilton-Dutoit SJ, Borghammer P. Pathological alpha-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. Ann Neurol. (2016) 79:940–9. doi: 10.1002/ana.24648

PubMed Abstract | CrossRef Full Text | Google Scholar

161. Knudsen K, Fedorova TD, Bekker AC, Iversen P, Østergaard K, Krogh K, et al. Objective colonic dysfunction is far more prevalent than subjective constipation in Parkinson's disease: a colon transit and volume study. J Parkinsons Dis. (2017) 7:359–67. doi: 10.3233/JPD-161050

PubMed Abstract | CrossRef Full Text | Google Scholar

162. Del Tredici K, Braak H. Review: sporadic Parkinson's disease: development and distribution of alpha-synuclein pathology. Neuropathol Appl Neurobiol. (2016) 42:33–50. doi: 10.1111/nan.12298

PubMed Abstract | CrossRef Full Text | Google Scholar

163. Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. (2012) 338:949–53. doi: 10.1126/science.1227157

PubMed Abstract | CrossRef Full Text | Google Scholar

164. Svensson E, Horváth-Puhó E, Thomsen RW, Djurhuus JC, Pedersen L, Borghammer P, et al. Vagotomy and subsequent risk of Parkinson's disease. Ann Neurol. (2015) 78:522–9. doi: 10.1002/ana.24448

PubMed Abstract | CrossRef Full Text | Google Scholar

165. Tysnes OB, Kenborg L, Herlofson K, Steding-Jessen M, Horn A, Olsen JH, et al. Does vagotomy reduce the risk of Parkinson's disease? Ann Neurol. (2015) 78:1011–2. doi: 10.1002/ana.24531

PubMed Abstract | CrossRef Full Text | Google Scholar

166. Liu B, Fang F, Pedersen NL, Tillander A, Ludvigsson JF, Ekbom A, et al. Vagotomy and Parkinson disease: a Swedish register-based matched-cohort study. Neurology. (2017) 88:1996–2002. doi: 10.1212/WNL.0000000000003961

PubMed Abstract | CrossRef Full Text | Google Scholar

167. Dinan TG, Cryan JF. Gut instincts: microbiota as a key regulator of brain development, ageing and neurodegeneration. J Physiol. (2017) 595:489–503. doi: 10.1113/JP273106

PubMed Abstract | CrossRef Full Text | Google Scholar

168. Abdel-Haq R, Schlachetzki JCM, Glass CK, Mazmanian SK. Microbiome-microglia connections via the gut-brain axis. J Exp Med. (2018) 216:41–59. doi: 10.1084/jem.20180794

PubMed Abstract | CrossRef Full Text | Google Scholar

169. Mayer EA, Knight R, Mazmanian SK, Cryan JF, Tillisch K. Gut microbes and the brain: paradigm shift in neuroscience. J Neurosci. (2014) 34:15490–6. doi: 10.1523/JNEUROSCI.3299-14.2014

PubMed Abstract | CrossRef Full Text | Google Scholar

170. Sun MF, Zhu YL, Zhou ZL, Jia XB, Xu YD, Yang Q, et al. Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson's disease mice: gut microbiota, glial reaction and TLR4/TNF-alpha signaling pathway. Brain Behav Immun. (2018) 70:48–60. doi: 10.1016/j.bbi.2018.02.005

PubMed Abstract | CrossRef Full Text | Google Scholar

171. Mulak A, Bonaz B. Brain-gut-microbiota axis in Parkinson's disease. World J Gastroenterol. (2015) 21:10609–20. doi: 10.3748/wjg.v21.i37.10609

PubMed Abstract | CrossRef Full Text | Google Scholar

172. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci. (2007) 8:57–69. doi: 10.1038/nrn2038

PubMed Abstract | CrossRef Full Text | Google Scholar

173. De Vadder F, Kovatcheva-Datchary P, Goncalves D, Vinera J, Zitoun C, Duchampt A, et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell. (2014) 156:84–96. doi: 10.1016/j.cell.2013.12.016

PubMed Abstract | CrossRef Full Text | Google Scholar

174. Athauda D, Foltynie T, The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action. Drug Discov Tdy. (2016) 21:802–18. doi: 10.1016/j.drudis.2016.01.013

CrossRef Full Text | Google Scholar

175. Obrenovich MEM. Leaky gut, leaky brain? Microorganisms. (2018) 6:107. doi: 10.3390/microorganisms6040107

PubMed Abstract | CrossRef Full Text | Google Scholar

176. Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut. (1987) 28:1221–7. doi: 10.1136/gut.28.10.1221

PubMed Abstract | CrossRef Full Text | Google Scholar

177. Ganapathy V, Thangaraju M, Prasad PD, Martin PM, Singh N. Transporters and receptors for short-chain fatty acids as the molecular link between colonic bacteria and the host. Curr Opin Pharmacol. (2013) 13:869–74. doi: 10.1016/j.coph.2013.08.006

PubMed Abstract | CrossRef Full Text | Google Scholar

178. Hong J, Jia Y, Pan S, Jia L, Li H, Han Z, et al. Butyrate alleviates high fat diet-induced obesity through activation of adiponectin-mediated pathway and stimulation of mitochondrial function in the skeletal muscle of mice. Oncotarget. (2016) 7:56071–82. doi: 10.18632/oncotarget.11267

PubMed Abstract | CrossRef Full Text | Google Scholar

179. Gruber J, Kennedy BK. Microbiome and longevity: gut microbes send signals to host mitochondria. Cell. (2017) 169:1168–9. doi: 10.1016/j.cell.2017.05.048

PubMed Abstract | CrossRef Full Text | Google Scholar

180. Tan J, McKenzie C, Vuillermin PJ, Goverse G, Vinuesa CG, Mebius RE, et al. Dietary fiber and bacterial SCFA enhance oral tolerance and protect against food allergy through diverse cellular pathways. Cell Rep. (2016) 15:2809–24. doi: 10.1016/j.celrep.2016.05.047

PubMed Abstract | CrossRef Full Text | Google Scholar

181. Clairembault T, Leclair-Visonneau L, Coron E, Bourreille A, Le Dily S, Vavasseur F, et al. Structural alterations of the intestinal epithelial barrier in Parkinson's disease. Acta Neuropathol Commun. (2015) 3:12. doi: 10.1186/s40478-015-0196-0

PubMed Abstract | CrossRef Full Text | Google Scholar

182. Schwiertz A, Spiegel J, Dillmann U, Grundmann D, Bürmann J, Faßbender K, et al. Fecal markers of intestinal inflammation and intestinal permeability are elevated in Parkinson's disease. Parkinsonism Relat Disord. (2018) 50:104–7. doi: 10.1016/j.parkreldis.2018.02.022

PubMed Abstract | CrossRef Full Text | Google Scholar

183. Weimers P, Halfvarson J, Sachs MC, Saunders-Pullman R, Ludvigsson JF, Peter I, et al. Inflammatory bowel disease and Parkinson's disease: a nationwide Swedish Cohort Study. Inflamm Bowel Dis. (2018) 25:111–23. doi: 10.1093/ibd/izy190

PubMed Abstract | CrossRef Full Text | Google Scholar

184. Villumsen M, Aznar S, Pakkenberg B, Jess T, Brudek T. Inflammatory bowel disease increases the risk of Parkinson's disease: a Danish nationwide cohort study 1977-2014. Gut. (2018) 68:18–24. doi: 10.1136/gutjnl-2017-315666

PubMed Abstract | CrossRef Full Text | Google Scholar

185. Peter I, Dubinsky M, Bressman S, Park A, Lu C, Chen N, et al. Anti-tumor necrosis factor therapy and incidence of Parkinson disease among patients with inflammatory bowel disease. JAMA Neurol. (2018) 75:939–46. doi: 10.1001/jamaneurol.2018.0605

PubMed Abstract | CrossRef Full Text | Google Scholar

186. Lin JC, Lin CS, Hsu CW, Lin CL, Kao CH. Association between Parkinson's disease and inflammatory bowel disease: a nationwide Taiwanese retrospective cohort study. Inflamm Bowel Dis. (2016) 22:1049–55. doi: 10.1097/MIB.0000000000000735

PubMed Abstract | CrossRef Full Text | Google Scholar

187. Zhu F, Li C, Gong J, Zhu W, Gu L, Li N. The risk of Parkinson's disease in inflammatory bowel disease: a systematic review and meta-analysis. Dig Liver Dis. (2019) 51:38–42. doi: 10.1016/j.dld.2018.09.017

PubMed Abstract | CrossRef Full Text | Google Scholar

188. Villarán RF, Espinosa-Oliva AM, Sarmiento M, De Pablos RM, Argüelles S, Delgado-Cortés MJ, et al. Ulcerative colitis exacerbates lipopolysaccharide-induced damage to the nigral dopaminergic system: potential risk factor in Parkinson's disease. J Neurochem. (2010) 114:1687–700. doi: 10.1111/j.1471-4159.2010.06879.x

CrossRef Full Text | Google Scholar

189. Kishimoto Y, Zhu W, Hosoda W, Sen JM, Mattson MP. Chronic mild gut inflammation accelerates brain neuropathology and motor dysfunction in alpha-synuclein mutant mice. Neuromolecular Med. (2019) 21:239–49. doi: 10.1007/s12017-019-08539-5

PubMed Abstract | CrossRef Full Text | Google Scholar

190. Camacho-Soto A, Gross A, Searles Nielsen S, Dey N, Racette BA. Inflammatory bowel disease and risk of Parkinson's disease in Medicare beneficiaries. Parkinsonism Relat Disord. (2018) 50:23–28. doi: 10.1016/j.parkreldis.2018.02.008

PubMed Abstract | CrossRef Full Text | Google Scholar

191. Xiong Y, Dawson TM, Dawson VL. Models of LRRK2-associated Parkinson's disease. Adv Neurobiol. (2017) 14:163–91. doi: 10.1007/978-3-319-49969-7_9

PubMed Abstract | CrossRef Full Text | Google Scholar

192. Kowalski K, Mulak A. Brain-gut-microbiota axis in Alzheimer's disease. J Neurogastroenterol Motil. (2019) 25:48–60. doi: 10.5056/jnm18087

PubMed Abstract | CrossRef Full Text | Google Scholar

193. Zhang R, Miller RG, Gascon R, Champion S, Katz J, Lancero M, et al. Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis (sALS). J Neuroimmunol. (2009) 206:121–4. doi: 10.1016/j.jneuroim.2008.09.017

PubMed Abstract | CrossRef Full Text | Google Scholar

194. Zhao Y, Cong L, Jaber V, Lukiw WJ. Microbiome-derived lipopolysaccharide enriched in the perinuclear region of Alzheimer's disease brain. Front Immunol. (2017) 8:1064. doi: 10.3389/fimmu.2017.01064

PubMed Abstract | CrossRef Full Text | Google Scholar

195. Rera M, Clark RI, Walker DW. Intestinal barrier dysfunction links metabolic and inflammatory markers of aging to death in Drosophila. Proc Natl Acad Sci USA. (2012) 109:21528–33. doi: 10.1073/pnas.1215849110

PubMed Abstract | CrossRef Full Text | Google Scholar

196. Lustgarten MS. Classifying aging as a disease: the role of microbes. Front Genet. (2016) 7:212. doi: 10.3389/fgene.2016.00212

PubMed Abstract | CrossRef Full Text | Google Scholar

197. Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS, et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia. (2007) 55:453–62. doi: 10.1002/glia.20467

PubMed Abstract | CrossRef Full Text | Google Scholar

198. de Kivit S, Tobin MC, Forsyth CB, Keshavarzian A, Landay AL. Regulation of intestinal immune responses through TLR activation: implications for pro- and prebiotics. Front Immunol. (2014) 5:60. doi: 10.3389/fimmu.2014.00060

PubMed Abstract | CrossRef Full Text | Google Scholar

199. Park BS, Lee JO. Recognition of lipopolysaccharide pattern by TLR4 complexes. Exp Mol Med. (2013) 45:e66. doi: 10.1038/emm.2013.97

PubMed Abstract | CrossRef Full Text | Google Scholar

200. Liu Y, Qin L, Wilson B, Wu X, Qian L, Granholm AC, et al. Endotoxin induces a delayed loss of TH-IR neurons in substantia nigra and motor behavioral deficits. Neurotoxicology. (2008) 29:864–70. doi: 10.1016/j.neuro.2008.02.014

PubMed Abstract | CrossRef Full Text | Google Scholar

201. Caputi V, Giron MC. Microbiome-gut-brain axis and toll-like receptors in Parkinson's disease. Int J Mol Sci. (2018) 19:E1689. doi: 10.3390/ijms19061689

PubMed Abstract | CrossRef Full Text | Google Scholar

202. Noelker C, Morel L, Lescot T, Osterloh A, Alvarez-Fischer D, Breloer M, et al. Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease. Sci Rep. (2013) 3:1393. doi: 10.1038/srep01393

PubMed Abstract | CrossRef Full Text | Google Scholar

203. Köhler CA, Maes M, Slyepchenko A, Berk M, Solmi M, Lanctôt KL, et al. The gut-brain axis, including the microbiome, leaky gut and bacterial translocation: mechanisms and pathophysiological role in Alzheimer's disease. Curr Pharm Des. (2016) 22:6152–66. doi: 10.2174/1381612822666160907093807

PubMed Abstract | CrossRef Full Text | Google Scholar

204. Buford TW, Carter CS, VanDerPol WJ, Chen D, Lefkowitz EJ, Eipers P, et al. Composition and richness of the serum microbiome differ by age and link to systemic inflammation. Geroscience. (2018) 40:257–68. doi: 10.1007/s11357-018-0026-y

PubMed Abstract | CrossRef Full Text | Google Scholar

205. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. (2008) 57:1470–81. doi: 10.2337/db07-1403

PubMed Abstract | CrossRef Full Text | Google Scholar

206. Song L, Pei L, Yao S, Wu Y, Shang Y. NLRP3 inflammasome in neurological diseases, from functions to therapies. Front Cell Neurosci. (2017) 11:63. doi: 10.3389/fncel.2017.00063

PubMed Abstract | CrossRef Full Text | Google Scholar

207. Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of action, role in disease, therapeutics. Nat Med. (2015) 21:677–87. doi: 10.1038/nm.3893

PubMed Abstract | CrossRef Full Text | Google Scholar

208. Freeman LC, Ting JP. The pathogenic role of the inflammasome in neurodegenerative diseases. J Neurochem. (2015) 136(Suppl. 1):29–38. doi: 10.1111/jnc.13217

PubMed Abstract | CrossRef Full Text | Google Scholar

209. He Y, Hara H, Nunez G. Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem Sci. (2016) 41:1012–1021. doi: 10.1016/j.tibs.2016.09.002

PubMed Abstract | CrossRef Full Text | Google Scholar

210. Walsh JG, Muruve DA, Power C. Inflammasomes in the CNS. Nat Rev Neurosci. (2014) 15:84–97. doi: 10.1038/nrn3638

PubMed Abstract | CrossRef Full Text | Google Scholar

211. Schroder K, Zhou R, Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger? Science. (2010) 327:296–300. doi: 10.1126/science.1184003

PubMed Abstract | CrossRef Full Text | Google Scholar

212. Codolo G, Plotegher N, Pozzobon T, Brucale M, Tessari I, Bubacco L, et al. Triggering of inflammasome by aggregated alpha-synuclein, an inflammatory response in synucleinopathies. PLoS ONE. (2013) 8:e55375. doi: 10.1371/journal.pone.0055375

PubMed Abstract | CrossRef Full Text | Google Scholar

213. Elliott EI, Sutterwala FS. Initiation and perpetuation of NLRP3 inflammasome activation and assembly. Immunol Rev. (2015) 265:35–52. doi: 10.1111/imr.12286

PubMed Abstract | CrossRef Full Text | Google Scholar

214. Lee E, Hwang I, Park S, Hong S, Hwang B, Cho Y, et al. MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration. Cell Death Differ. (2018) 26:213–28. doi: 10.1038/s41418-018-0124-5

PubMed Abstract | CrossRef Full Text | Google Scholar

215. Sarkar S, Malovic E, Harishchandra DS, Ghaisas S, Panicker N, Charli A, et al. Mitochondrial impairment in microglia amplifies NLRP3 inflammasome proinflammatory signaling in cell culture and animal models of Parkinson's disease. NPJ Parkinsons Dis. (2017) 3:30. doi: 10.1038/s41531-017-0032-2

PubMed Abstract | CrossRef Full Text | Google Scholar

216. Giacoppo S, Bramanti P, Mazzon E. Triggering of inflammasome by impaired autophagy in response to acute experimental Parkinson's disease: involvement of the PI3K/Akt/mTOR pathway. Neuroreport. (2017) 28:996–1007. doi: 10.1097/WNR.0000000000000871

PubMed Abstract | CrossRef Full Text | Google Scholar

217. Gong Z, Pan J, Shen Q, Li M, Peng Y. Mitochondrial dysfunction induces NLRP3 inflammasome activation during cerebral ischemia/reperfusion injury. J Neuroinflammation. (2018) 15:242. doi: 10.1186/s12974-018-1282-6

PubMed Abstract | CrossRef Full Text | Google Scholar

218. Youm YH, Grant RW, McCabe LR, Albarado DC, Nguyen KY, Ravussin A, et al. Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging. Cell Metab. (2013) 18:519–32. doi: 10.1016/j.cmet.2013.09.010

PubMed Abstract | CrossRef Full Text | Google Scholar

219. Heneka MT. Inflammasome activation and innate immunity in Alzheimer's disease. Brain Pathol. (2017) 27:220–2. doi: 10.1111/bpa.12483

PubMed Abstract | CrossRef Full Text | Google Scholar

220. Anderson FL, Coffey MM, Berwin BL, Havrda MC. Inflammasomes: an emerging mechanism translating environmental toxicant exposure into neuroinflammation in Parkinson's disease. Toxicol Sci. (2018) 166:3–15. doi: 10.1093/toxsci/kfy219

PubMed Abstract | CrossRef Full Text | Google Scholar

221. Chakraborty S, Kaushik DK, Gupta M, Basu A. Inflammasome signaling at the heart of central nervous system pathology. J Neurosci Res. (2010) 88:1615–31. doi: 10.1002/jnr.22343

PubMed Abstract | CrossRef Full Text | Google Scholar

222. Pavillard LE, Cañadas-Lozano D, Alcocer-Gómez E, Marín-Aguilar F, Pereira S, Robertson AAB, et al. NLRP3-inflammasome inhibition prevents high fat and high sugar diets-induced heart damage through autophagy induction. Oncotarget. (2017) 8:99740–56. doi: 10.18632/oncotarget.20763

PubMed Abstract | CrossRef Full Text | Google Scholar

223. Jena PK, Sheng L, Di Lucente J, Jin LW, Maezawa I, Wan YY. Dysregulated bile acid synthesis and dysbiosis are implicated in Western diet-induced systemic inflammation, microglial activation, reduced neuroplasticity. FASEB J. (2018) 32:2866–77. doi: 10.1096/fj.201700984RR

PubMed Abstract | CrossRef Full Text | Google Scholar

224. Guo C, Xie S, Chi Z, Zhang J, Liu Y, Zhang L, et al. Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome. Immunity. (2016) 45:802–16. doi: 10.1016/j.immuni.2016.10.009

CrossRef Full Text | Google Scholar

225. Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med. (2011) 17:179–88. doi: 10.1038/nm.2279

PubMed Abstract | CrossRef Full Text | Google Scholar

226. Stienstra R, van Diepen JA, Tack CJ, Zaki MH, van de Veerdonk FL, Perera D, et al. Inflammasome is a central player in the induction of obesity and insulin resistance. Proc Natl Acad Sci USA. (2011) 108:15324–9. doi: 10.1073/pnas.1100255108

PubMed Abstract | CrossRef Full Text | Google Scholar

227. Bloom GS, Lazo JS, Norambuena A. Reduced brain insulin signaling: a seminal process in Alzheimer's disease pathogenesis. Neuropharmacology. (2017) 136(Pt B):192–5. doi: 10.1016/j.neuropharm.2017.09.016

PubMed Abstract | CrossRef Full Text | Google Scholar

228. Athauda D, Foltynie T. Insulin resistance and Parkinson's disease: a new target for disease modification? Prog Neurobiol. (2016) 145–146:98–120. doi: 10.1016/j.pneurobio.2016.10.001

PubMed Abstract | CrossRef Full Text | Google Scholar

229. Aviles-Olmos I, Limousin P, Lees A, Foltynie T. Parkinson's disease, insulin resistance and novel agents of neuroprotection. Brain. (2013) 136(Pt 2):374–84. doi: 10.1093/brain/aws009

PubMed Abstract | CrossRef Full Text | Google Scholar

230. Wang J, Jia H. Metagenome-wide association studies: fine-mining the microbiome. Nat Rev Microbiol. (2016) 14:508–22. doi: 10.1038/nrmicro.2016.83

PubMed Abstract | CrossRef Full Text | Google Scholar

231. De Pablo-Fernandez E, Goldacre R, Pakpoor J, Noyce AJ, Warner TT. Association between diabetes and subsequent Parkinson disease: a record-linkage cohort study. Neurology. (2018) 91:e139–42. doi: 10.1212/WNL.0000000000005771

CrossRef Full Text | Google Scholar

232. Alters SE, McLaughlin B, Spink B, Lachinyan T, Wang CW, Podust V, et al. Integrative network analysis unveils convergent molecular pathways in Parkinson's disease and diabetes. PLoS ONE. (2013) 8:e83940. doi: 10.1371/journal.pone.0083940

CrossRef Full Text | Google Scholar

233. Wahlqvist ML, Lee MS, Hsu CC, Chuang SY, Lee JT, Tsai HN. Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort. Parkinsonism Relat Disord. (2012) 18:753–8. doi: 10.1016/j.parkreldis.2012.03.010

PubMed Abstract | CrossRef Full Text | Google Scholar

234. Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J. Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care. (2007) 30:842–7. doi: 10.2337/dc06-2011

PubMed Abstract | CrossRef Full Text | Google Scholar

235. Karlsson FH, Tremaroli V, Nookaew I, Bergström G, Behre CJ, Fagerberg B, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. (2013) 498:99–103. doi: 10.1038/nature12198

PubMed Abstract | CrossRef Full Text | Google Scholar

236. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. (2012) 490:55–60. doi: 10.1038/nature11450

PubMed Abstract | CrossRef Full Text | Google Scholar

237. Coll RC, Robertson AA, Chae JJ, Higgins SC, Muñoz-Planillo R, Inserra MC, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. (2015) 21:248–55. doi: 10.1038/nm.3806

PubMed Abstract | CrossRef Full Text | Google Scholar

238. Chen L, Xue L, Zheng J, Tian X, Zhang Y, Tong Q. PPARss/delta agonist alleviates NLRP3 inflammasome-mediated neuroinflammation in the MPTP mouse model of Parkinson's disease. Behav Brain Res. (2018) 356:483–9. doi: 10.1016/j.bbr.2018.06.005

PubMed Abstract | CrossRef Full Text | Google Scholar

239. Bian F, Xiao Y, Zaheer M, Volpe EA, Pflugfelder SC, Li DQ, et al. Inhibition of NLRP3 inflammasome pathway by butyrate improves corneal wound healing in corneal alkali burn. Int J Mol Sci. (2017) 18:E562. doi: 10.3390/ijms18030562

PubMed Abstract | CrossRef Full Text | Google Scholar

240. Abderrazak A, El Hadri K, Bosc E, Blondeau B, Slimane MN, Büchele B, et al. Inhibition of the inflammasome NLRP3 by arglabin attenuates inflammation, protects pancreatic beta-cells from apoptosis, prevents type 2 diabetes mellitus development in ApoE2Ki mice on a chronic high-fat diet. J Pharmacol Exp Ther. (2016) 357:487–94. doi: 10.1124/jpet.116.232934

PubMed Abstract | CrossRef Full Text | Google Scholar

241. Bodnaruc AM, Prud'homme D, Blanchet R, Giroux I. Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review. Nutr Metab. (2016) 13:92. doi: 10.1186/s12986-016-0153-3

PubMed Abstract | CrossRef Full Text | Google Scholar

242. Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. (2011) 61:364–71. doi: 10.2337/db11-1019

PubMed Abstract | CrossRef Full Text | Google Scholar

243. Tolhurst G, Reimann F, Gribble FM. Nutritional regulation of glucagon-like peptide-1 secretion. J Physiol. (2009) 587:27–32. doi: 10.1113/jphysiol.2008.164012

PubMed Abstract | CrossRef Full Text | Google Scholar

244. Chen A, Chen Z, Xia Y, Lu D, Yang X, Sun A, et al. Liraglutide attenuates NLRP3 inflammasome-dependent pyroptosis via regulating SIRT1/NOX4/ROS pathway in H9c2 cells. Biochem Biophys Res Commun. (2018) 499:267–72. doi: 10.1016/j.bbrc.2018.03.142

PubMed Abstract | CrossRef Full Text | Google Scholar

245. Dai Y, Dai D, Wang X, Ding Z, Mehta JL. DPP-4 inhibitors repress NLRP3 inflammasome and interleukin-1beta via GLP-1 receptor in macrophages through protein kinase C pathway. Cardiovasc Drugs Ther. (2014) 28:425–32. doi: 10.1007/s10557-014-6539-4

PubMed Abstract | CrossRef Full Text | Google Scholar

246. Kim S, Moon M, Park S, Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease. J Endocrinol. (2009) 202:431–9. doi: 10.1677/JOE-09-0132

CrossRef Full Text | Google Scholar

247. Holscher C. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J Endocrinol. (2014) 221:T31–41. doi: 10.1530/JOE-13-0221

PubMed Abstract | CrossRef Full Text | Google Scholar

248. Kim DS, Choi HI, Wang Y, Luo Y, Hoffer BJ, Greig NH. A new treatment strategy for Parkinson's disease through the gut-brain axis: the glucagon-like peptide-1 receptor pathway. Cell Transplant. (2017) 26:1560–71. doi: 10.1177/0963689717721234

PubMed Abstract | CrossRef Full Text | Google Scholar

249. Katsurada K, Yada T. Neural effects of gut- and brain-derived glucagon-like peptide-1 and its receptor agonist. J Diabetes Investig. (2016) 7(Suppl. 1):64–9. doi: 10.1111/jdi.12464

PubMed Abstract | CrossRef Full Text | Google Scholar

250. Mercado NM, Collier TJ, Sortwell CE, Steece-Collier K. BDNF in the aged brain: translational implications for Parkinson's disease. Austin Neurol Neurosci. (2017) 2:1021.

PubMed Abstract | Google Scholar

251. Wang Y, Liu H, Zhang BS, Soares JC, Zhang XY. Low BDNF is associated with cognitive impairments in patients with Parkinson's disease. Parkinsonism Relat Disord. (2016) 29:66–71. doi: 10.1016/j.parkreldis.2016.05.023

PubMed Abstract | CrossRef Full Text | Google Scholar

252. Yamane S, Inagaki N. Regulation of glucagon-like peptide-1 sensitivity by gut microbiota dysbiosis. J Diabetes Investig. (2017) 9:262–4. doi: 10.1111/jdi.12762

PubMed Abstract | CrossRef Full Text | Google Scholar

253. Kappe C, Tracy LM, Patrone C, Iverfeldt K, Sjöholm Å. GLP-1 secretion by microglial cells and decreased CNS expression in obesity. J Neuroinflammation. (2012) 9:276. doi: 10.1186/1742-2094-9-276

PubMed Abstract | CrossRef Full Text | Google Scholar

254. Bercik P, Denou E, Collins J, Jackson W, Lu J, Jury J, et al. The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. Gastroenterology. (2011) 141:599–609, 609.e1–3. doi: 10.1053/j.gastro.2011.04.052

PubMed Abstract | CrossRef Full Text | Google Scholar

255. Feng P, Zhang X, Li D, Ji C, Yuan Z, Wang R, et al. Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease. Neuropharmacology. (2018) 133:385–94. doi: 10.1016/j.neuropharm.2018.02.012

PubMed Abstract | CrossRef Full Text | Google Scholar

256. Ji C, Xue G-F, Lijun C, Feng P, Li D, Li G, et al. A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BND. Brain Res. (2015) 1634:1–11. doi: 10.1016/j.brainres.2015.09.035

CrossRef Full Text | Google Scholar

257. Athauda D, Foltynie T. Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease. Neuropharmacology. (2018) 136(Pt B):260–70. doi: 10.1016/j.neuropharm.2017.09.023

PubMed Abstract | CrossRef Full Text | Google Scholar

258. Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, et al. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet. (2017) 390:1664–75. doi: 10.1016/S0140-6736(17)31585-4

PubMed Abstract | CrossRef Full Text | Google Scholar

259. Cani PD, Everard A. Talking microbes: When gut bacteria interact with diet and host organs. Mol Nutr Food Res. (2016) 60:58–66. doi: 10.1002/mnfr.201500406

PubMed Abstract | CrossRef Full Text | Google Scholar

260. O'Leary OF, Ogbonnaya ES, Felice D, Levone BR, C Conroy L, Fitzgerald P, et al. The vagus nerve modulates BDNF expression and neurogenesis in the hippocampus. Eur Neuropsychopharmacol. (2018) 28:307–316. doi: 10.1016/j.euroneuro.2017.12.004

PubMed Abstract | CrossRef Full Text | Google Scholar

261. Buchman AS, Yu L, Boyle PA, Schneider JA, De Jager PL, Bennett DA. Higher brain BDNF gene expression is associated with slower cognitive decline in older adults. Neurology. (2016) 86:735–41. doi: 10.1212/WNL.0000000000002387

PubMed Abstract | CrossRef Full Text | Google Scholar

262. Motamedi S, Karimi I, Jafari F. The interrelationship of metabolic syndrome and neurodegenerative diseases with focus on brain-derived neurotrophic factor (BDNF): kill two birds with one stone. Metab Brain Dis. (2014) 32:651–65. doi: 10.1007/s11011-017-9997-0

PubMed Abstract | CrossRef Full Text | Google Scholar

263. Barichello T, Generoso JS, Simões LR, Faller CJ, Ceretta RA, Petronilho F, et al. Sodium butyrate prevents memory impairment by re-establishing BDNF and GDNF expression in experimental pneumococcal meningitis. Mol Neurobiol. (2015) 52:734–40. doi: 10.1007/s12035-014-8914-3

PubMed Abstract | CrossRef Full Text | Google Scholar

264. Howells DW, Porritt MJ, Wong JY, Batchelor PE, Kalnins R, Hughes AJ, et al. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp Neurol. (2000) 166:127–35. doi: 10.1006/exnr.2000.7483

PubMed Abstract | CrossRef Full Text | Google Scholar

265. Rahmani F, Saghazadeh A, Rahmani M, Teixeira AL, Rezaei N, Aghamollaii V, et al. Plasma levels of brain-derived neurotrophic factor in patients with Parkinson disease: a systematic review and meta-analysis. Brain Res. (2018) 1704:127–36. doi: 10.1016/j.brainres.2018.10.006

PubMed Abstract | CrossRef Full Text | Google Scholar

266. Maqsood R, Stone TW. The gut-brain axis, BDNF, NMDA and CNS disorders. Neurochem Res. (2016) 41:2819–35. doi: 10.1007/s11064-016-2039-1

PubMed Abstract | CrossRef Full Text | Google Scholar

267. Sen T, Cawthon CR, Ihde BT, Hajnal A, DiLorenzo PM, de La Serre CB, et al. Diet-driven microbiota dysbiosis is associated with vagal remodeling and obesity. Physiol Behav. (2017) 173:305–17. doi: 10.1016/j.physbeh.2017.02.027

PubMed Abstract | CrossRef Full Text | Google Scholar

268. Erro R, Brigo F, Tamburin S, Zamboni M, Antonini A, Tinazzi M. Nutritional habits, risk, progression of Parkinson disease. J Neurol. (2017) 265:12–23. doi: 10.1007/s00415-017-8639-0

PubMed Abstract | CrossRef Full Text | Google Scholar

269. Gao X, Chen H, Fung TT, Logroscino G, Schwarzschild MA, Hu FB, et al. Prospective study of dietary pattern and risk of Parkinson disease. Am J Clin Nutr. (2007) 86:1486–94. doi: 10.1093/ajcn/86.5.1486

PubMed Abstract | CrossRef Full Text | Google Scholar

270. Alcalay RN, Gu Y, Mejia-Santana H, Cote L, Marder KS, Scarmeas N. The association between Mediterranean diet adherence and Parkinson's disease. Mov Disord. (2012) 27:771–4. doi: 10.1002/mds.24918

PubMed Abstract | CrossRef Full Text | Google Scholar

271. David LA, Materna AC, Friedman J, Campos-Baptista MI, Blackburn MC, Perrotta A, et al. Host lifestyle affects human microbiota on daily timescales. Genome Biol. (2014) 15:R89. doi: 10.1186/gb-2014-15-7-r89

PubMed Abstract | CrossRef Full Text | Google Scholar

272. Canfora EE, Jocken JW, Blaak EE. Short-chain fatty acids in control of body weight and insulin sensitivity. Nat Rev Endocrinol. (2015) 11:577–91. doi: 10.1038/nrendo.2015.128

PubMed Abstract | CrossRef Full Text | Google Scholar

273. Canfora EE, van der Beek CM, Jocken JWE, Goossens GH, Holst JJ, Olde Damink SWM, et al. Colonic infusions of short-chain fatty acid mixtures promote energy metabolism in overweight/obese men: a randomized crossover trial. Sci Rep. (2017) 7:2360. doi: 10.1038/s41598-017-02546-x

PubMed Abstract | CrossRef Full Text | Google Scholar

274. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. (2009) 9:311–26. doi: 10.1016/j.cmet.2009.02.002

PubMed Abstract | CrossRef Full Text | Google Scholar

275. Tozser J, Benko S. Natural compounds as regulators of NLRP3 inflammasome-mediated IL-1β production. Mediators Inflamm. (2016) 2016:5460302. doi: 10.1155/2016/5460302

PubMed Abstract | CrossRef Full Text | Google Scholar

276. Mattson MP, Longo VD, Harvie M. Impact of intermittent fasting on health and disease processes. Ageing Res Rev. (2016) 39:46–58. doi: 10.1016/j.arr.2016.10.005

PubMed Abstract | CrossRef Full Text | Google Scholar

277. Mattson MP, Arumugam TV. Hallmarks of brain aging: adaptive and pathological modification by metabolic states. Cell Metab. (2018) 27:1176–99. doi: 10.1016/j.cmet.2018.05.011

PubMed Abstract | CrossRef Full Text | Google Scholar

278. Mattson MP, Moehl K, Ghena N, Schmaedick M, Cheng A. Intermittent metabolic switching, neuroplasticity and brain health. Nat Rev Neurosci. (2018) 19:63–80. doi: 10.1038/nrn.2017.156

PubMed Abstract | CrossRef Full Text | Google Scholar

279. Norwitz NG, Hu MT, Clarke K. The mechanisms by which the ketone body D-β-hydroxybutyrate may improve the multiple cellular pathologies of Parkinson's disease. Front Nutr. (2019) 6:63. doi: 10.3389/fnut.2019.00063

PubMed Abstract | CrossRef Full Text | Google Scholar

280. Longo VD, Mattson MP. Fasting: molecular mechanisms and clinical applications. Cell Metab. (2014) 19:181–92. doi: 10.1016/j.cmet.2013.12.008

PubMed Abstract | CrossRef Full Text | Google Scholar

281. Duan W, Mattson MP. Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease. J Neurosci Res. (1999) 57:195–206.

PubMed Abstract | Google Scholar

282. Maswood N, Young J, Tilmont E, Zhang Z, Gash DM, Gerhardt GA, et al. Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease. Proc Natl Acad Sci USA. (2004) 101:18171–6. doi: 10.1073/pnas.0405831102

PubMed Abstract | CrossRef Full Text | Google Scholar

283. Maalouf M, Rho JM, Mattson MP. The neuroprotective properties of calorie restriction, the ketogenic diet, ketone bodies. Brain Res Rev. (2009) 59:293–315. doi: 10.1016/j.brainresrev.2008.09.002

PubMed Abstract | CrossRef Full Text | Google Scholar

284. Vanitallie TB, Nonas C, Di Rocco A, Boyar K, Hyams K, Heymsfield SB. Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study. Neurology. (2005) 64:728–30. doi: 10.1212/01.WNL.0000152046.11390.45

PubMed Abstract | CrossRef Full Text | Google Scholar

285. Cornille E, Abou-Hamdan M, Khrestchatisky M, Nieoullon A, de Reggi M, Gharib B. Enhancement of L-3-hydroxybutyryl-CoA dehydrogenase activity and circulating ketone body levels by pantethine. Relevance to dopaminergic injury. BMC Neurosci. (2010) 11:51. doi: 10.1186/1471-2202-11-51

PubMed Abstract | CrossRef Full Text | Google Scholar

286. Tieu K, Perier C, Caspersen C, Teismann P, Wu DC, Yan SD, et al. D-β-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J Clin Invest. (2003) 112:892–901. doi: 10.1172/JCI200318797

PubMed Abstract | CrossRef Full Text | Google Scholar

287. Youm YH, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D, et al. The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med. (2015) 21:263–9. doi: 10.1038/nm.3804

PubMed Abstract | CrossRef Full Text | Google Scholar

288. Traba J, Geiger SS, Kwarteng-Siaw M, Han K, Ra OH, Siegel RM, et al. Prolonged fasting suppresses mitochondrial NLRP3 inflammasome assembly and activation via SIRT3-mediated activation of superoxide dismutase 2. J Biol Chem. (2017) 292:12153–64. doi: 10.1074/jbc.M117.791715

PubMed Abstract | CrossRef Full Text | Google Scholar

289. Traba J, Kwarteng-Siaw M, Okoli TC, Li J, Huffstutler RD, Bray A, et al. Fasting and refeeding differentially regulate NLRP3 inflammasome activation in human subjects. J Clin Invest. (2015) 125:4592–600. doi: 10.1172/JCI83260

PubMed Abstract | CrossRef Full Text | Google Scholar

290. Goldberg EL, Asher JL, Molony RD, Shaw AC, Zeiss CJ, Wang C, et al. β-hydroxybutyrate deactivates neutrophil NLRP3 inflammasome to relieve gout flares. Cell Rep. (2017) 18:2077–87. doi: 10.1016/j.celrep.2017.02.004

PubMed Abstract | CrossRef Full Text | Google Scholar

291. Li G, Xie C, Lu S, Nichols RG, Tian Y, Li L, et al. Intermittent fasting promotes white adipose browning and decreases obesity by shaping the gut microbiota. Cell Metab. (2017) 26:672–685.e4. doi: 10.1016/j.cmet.2017.08.019

CrossRef Full Text | Google Scholar

292. Beli E, Yan Y, Moldovan L, Vieira CP, Gao R, Duan Y, et al. Restructuring of the gut microbiome by intermittent fasting prevents retinopathy and prolongs survival in db/db mice. Diabetes. (2018) 67:1867–79. doi: 10.2337/db18-0158

PubMed Abstract | CrossRef Full Text | Google Scholar

293. Moon M, Kim HG, Hwang L, Seo JH, Kim S, Hwang S, et al. Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation. Neurotox Res. (2009) 15:332–47. doi: 10.1007/s12640-009-9037-x

PubMed Abstract | CrossRef Full Text | Google Scholar

294. Bayliss JA, Andrews ZB. Ghrelin is neuroprotective in Parkinson's disease: molecular mechanisms of metabolic neuroprotection. Ther Adv Endocrinol Metab. (2013) 4:25–36. doi: 10.1177/2042018813479645

PubMed Abstract | CrossRef Full Text | Google Scholar

295. Andrews ZB, Erion D, Beiler R, Liu ZW, Abizaid A, Zigman J, et al. Ghrelin promotes and protects nigrostriatal dopamine function via a UCP2-dependent mitochondrial mechanism. J Neurosci. (2009) 29:14057–65. doi: 10.1523/JNEUROSCI.3890-09.2009

PubMed Abstract | CrossRef Full Text | Google Scholar

296. Dyall SC. Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. Front Aging Neurosci. (2015) 7:52. doi: 10.3389/fnagi.2015.00052

PubMed Abstract | CrossRef Full Text | Google Scholar

297. da Silva TM, Munhoz RP, Alvarez C, Naliwaiko K, Kiss A, Andreatini R, et al. Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. J Affect Disord. (2008) 111:351–9. doi: 10.1016/j.jad.2008.03.008

PubMed Abstract | CrossRef Full Text | Google Scholar

298. Luchtman DW, Meng Q, Song C. Ethyl-eicosapentaenoate (E-EPA) attenuates motor impairments and inflammation in the MPTP-probenecid mouse model of Parkinson's disease. Behav Brain Res. (2012) 226:386–96. doi: 10.1016/j.bbr.2011.09.033

PubMed Abstract | CrossRef Full Text | Google Scholar

299. Taepavarapruk P, Song C. Reductions of acetylcholine release and nerve growth factor expression are correlated with memory impairment induced by interleukin-1β administrations: effects of omega-3 fatty acid EPA treatment. J Neurochem. (2010) 112:1054–64. doi: 10.1111/j.1471-4159.2009.06524.x

PubMed Abstract | CrossRef Full Text | Google Scholar

300. Meng Q, Luchtman DW, El Bahh B, Zidichouski JA, Yang J, Song C. Ethyl-eicosapentaenoate modulates changes in neurochemistry and brain lipids induced by parkinsonian neurotoxin 1-methyl-4-phenylpyridinium in mouse brain slices. Eur J Pharmacol. (2010) 649:127–34. doi: 10.1016/j.ejphar.2010.09.046

PubMed Abstract | CrossRef Full Text | Google Scholar

301. Luchtman DW, Meng Q, Wang X, Shao D, Song C. omega-3 fatty acid eicosapentaenoic acid attenuates MPP+-induced neurodegeneration in fully differentiated human SH-SY5Y and primary mesencephalic cells. J Neurochem. (2013) 124:855–68. doi: 10.1111/jnc.12068

PubMed Abstract | CrossRef Full Text | Google Scholar

302. Cansev M, Ulus IH, Wang L, Maher TJ, Wurtman RJ. Restorative effects of uridine plus docosahexaenoic acid in a rat model of Parkinson's disease. Neurosci Res. (2008) 62:206–9. doi: 10.1016/j.neures.2008.07.005

PubMed Abstract | CrossRef Full Text | Google Scholar

303. Perez-Pardo P, de Jong EM, Broersen LM, van Wijk N, Attali A, Garssen J, et al. Promising effects of neurorestorative diets on motor, cognitive, gastrointestinal dysfunction after symptom development in a mouse model of Parkinson's disease. Front Aging Neurosci. (2017) 9:57. doi: 10.3389/fnagi.2017.00057

PubMed Abstract | CrossRef Full Text | Google Scholar

304. Ozsoy O, Seval-Celik Y, Hacioglu G, Yargicoglu P, Demir R, Agar A, et al. The influence and the mechanism of docosahexaenoic acid on a mouse model of Parkinson's disease. Neurochem Int. (2011) 59:664–70. doi: 10.1016/j.neuint.2011.06.012

PubMed Abstract | CrossRef Full Text | Google Scholar

305. Calon F, Lim GP, Morihara T, Yang F, Ubeda O, Salem N, et al. Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease. Eur J Neurosci. (2005) 22:617–26. doi: 10.1111/j.1460-9568.2005.04253.x

PubMed Abstract | CrossRef Full Text | Google Scholar

306. Green KN, Martinez-Coria H, Khashwji H, Hall EB, Yurko-Mauro KA, Ellis L, et al. Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. J Neurosci. (2007) 27:4385–95. doi: 10.1523/JNEUROSCI.0055-07.2007

PubMed Abstract | CrossRef Full Text | Google Scholar

307. Sakamoto T, Cansev M, Wurtman RJ. Oral supplementation with docosahexaenoic acid and uridine-5'-monophosphate increases dendritic spine density in adult gerbil hippocampus. Brain Res. (2007) 1182:50–9. doi: 10.1016/j.brainres.2007.08.089

PubMed Abstract | CrossRef Full Text | Google Scholar

308. Serhan CN, Petasis NA. Resolvins and protectins in inflammation resolution. Chem Rev. (2011) 111:5922–43. doi: 10.1021/cr100396c

PubMed Abstract | CrossRef Full Text | Google Scholar

309. Bazan NG. Cellular and molecular events mediated by docosahexaenoic acid-derived neuroprotectin D1 signaling in photoreceptor cell survival and brain protection. Prostaglandins Leukot Essent Fatty Acids. (2009) 81:205–11. doi: 10.1016/j.plefa.2009.05.024

PubMed Abstract | CrossRef Full Text | Google Scholar

310. Ren J, Meng S, Yan B, Yu J, Liu J. Protectin D1 reduces concanavalin A-induced liver injury by inhibiting NF-kappaB-mediated CX3CL1/CX3CR1 axis and NLR family, pyrin domain containing 3 inflammasome activation. Mol Med Rep. (2016) 13:3627–38. doi: 10.3892/mmr.2016.4980

PubMed Abstract | CrossRef Full Text | Google Scholar

311. Lin C, Chao H, Li Z, Xu X, Liu Y, Bao Z, et al. Omega-3 fatty acids regulate NLRP3 inflammasome activation and prevent behavior deficits after traumatic brain injury. Exp Neurol. (2017) 290:115–122. doi: 10.1016/j.expneurol.2017.01.005

PubMed Abstract | CrossRef Full Text | Google Scholar

312. Harvey LD, Yin Y, Attarwala IY, Begum G, Deng J, Yan HQ, et al. Administration of DHA reduces endoplasmic reticulum stress-associated inflammation and alters microglial or macrophage activation in traumatic brain injury. ASN Neuro. (2015) 7:1759091415618969. doi: 10.1177/1759091415618969

CrossRef Full Text | Google Scholar

313. Sui YH, Luo WJ, Xu QY, Hua J. Dietary saturated fatty acid and polyunsaturated fatty acid oppositely affect hepatic NOD-like receptor protein 3 inflammasome through regulating nuclear factor-kappa B activation. World J Gastroenterol. (2016) 22:2533–44. doi: 10.3748/wjg.v22.i8.2533

PubMed Abstract | CrossRef Full Text | Google Scholar

314. Yan Y, Jiang W, Spinetti T, Tardivel A, Castillo R, Bourquin C, et al. Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. Immunity. (2013) 38:1154–63. doi: 10.1016/j.immuni.2013.05.015

PubMed Abstract | CrossRef Full Text | Google Scholar

315. Calon F, Lim GP, Yang F, Morihara T, Teter B, Ubeda O, et al. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron. (2004) 43:633–45. doi: 10.1016/j.neuron.2004.08.013

PubMed Abstract | CrossRef Full Text | Google Scholar

316. Wu A, Ying Z, Gomez-Pinilla F. Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, counteract learning disability after traumatic brain injury in rats. J Neurotrauma. (2004) 21:1457–67. doi: 10.1089/neu.2004.21.1457

PubMed Abstract | CrossRef Full Text | Google Scholar

317. Hashimoto M, Tanabe Y, Fujii Y, Kikuta T, Shibata H, Shido O. Chronic administration of docosahexaenoic acid ameliorates the impairment of spatial cognition learning ability in amyloid beta-infused rats. J Nutr. (2005) 135:549–55. doi: 10.1093/jn/135.3.549

PubMed Abstract | CrossRef Full Text | Google Scholar

318. Moriguchi T, Greiner RS, Salem N Jr. Behavioral deficits associated with dietary induction of decreased brain docosahexaenoic acid concentration. J Neurochem. (2000) 75:2563–73. doi: 10.1046/j.1471-4159.2000.0752563.x

PubMed Abstract | CrossRef Full Text | Google Scholar

319. de Urquiza AM, Liu S, Sjöberg M, Zetterström RH, Griffiths W, Sjövall J, et al. Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science. (2000) 290:2140–4. doi: 10.1126/science.290.5499.2140

PubMed Abstract | CrossRef Full Text | Google Scholar